Trial Outcomes & Findings for Phase 1b Study Evaluating OPomD in Relapsed or Refractory Multiple Myeloma (NCT NCT02939183)

NCT ID: NCT02939183

Last Updated: 2024-09-26

Results Overview

DLTs were graded using the Common Terminology Criteria for Adverse Events (CTCAE) version 4.03 and included the below, if judged by the investigator/medical monitor to be possibly related to study treatment: Non-hematologic DLTs were any ≥ Grade 3 toxicity, except: Grade 3 asymptomatic electrolyte abnormalities (except hypophosphatemia \> 24 hours); Grade 3 nausea, vomiting and diarrhea \< 3 days; Grade 3 fatigue \< 14 days; ≥ Grade 3 hyperglycemia/toxicity due to dexamethasone; ≥ Grade 3 rash due to pomalidomide. Hematologic DLTs included: Grade 4 neutropenia if absolute neutrophil count \< 0.5 x 10\^9/L ≥ 7 days; febrile neutropenia; Grade 4 thrombocytopenia ≥ 7 days; Grade ≥ 3 with ≥ Grade 2 bleeding/requiring platelet transfusion.

• Recruitment status: COMPLETED
• Study phase: PHASE1
• Target enrollment: 61 participants
• Primary outcome timeframe: Day 1 to day 28 of cycle 1, where each cycle was 28 days
• Results posted on: 2024-09-26

Participant Flow

Participants were enrolled at 26 research centers in Australia, Canada, Spain, and the United States, and participated from 17 January 2017 to 06 October 2022.

Part 1 evaluated oprozomib formulations (immediate-release [IR] and gastro-retentive [GR]) administered at a 150 mg/day dose level with dexamethasone. Part 2 evaluated the IR and GR oprozomib formulations administered at different increasing dose levels with pomalidomide and dexamethasone. An open-label roll-over part was conducted in the United States to include eligible participants from separate Amgen oprozomib studies in a single arm as pre-specified in the statistical analysis plan (SAP).

Participant milestones

Measure	Oprozomib IR 150 mg/Day + Dexamethsone In Part 1, participants received oprozomib IR 150 mg/day administered orally every week on 2 consecutive days (2/7 schedule) in combination with dexamethasone 20 mg orally (days 1, 2, 8, 9, 15, 16, 22, and 23 of each 28-day cycle), for up to 10 months.	Oprozomib GR 150 mg/Day + Dexamethasone In Part 1, participants received oprozomib GR 150 mg/day administered orally every week on 2 consecutive days (2/7 schedule) in combination with dexamethasone 20 mg orally (days 1, 2, 8, 9, 15, 16, 22, and 23 of each 28-day cycle), for up to 10 months.	Oprozomib IR 150 mg/Day + Pomalidomide + Dexamethasone In Part 2, participants received oprozomib IR 150 mg/day administered orally every week on 2 consecutive days (2/7 schedule) in combination with dexamethasone 20 mg orally (days 1, 2, 8, 9, 15, 16, 22, and 23 of each 28-day cycle), for up to 10 months. Participants also received pomalidomide 4 mg orally once daily on days 1 to 21 of each 28-day cycle.	Oprozomib GR 150 mg/Day + Pomalidomide + Dexamethasone In Part 2, participants received oprozomib GR 150 mg/day administered orally every week on 2 consecutive days (2/7 schedule) in combination with dexamethasone 20 mg orally (days 1, 2, 8, 9, 15, 16, 22, and 23 of each 28-day cycle), for up to 10 months. Participants also received pomalidomide 4 mg orally once daily on days 1 to 21 of each 28-day cycle.	Oprozomib IR 200 mg/Day + Pomalidomide + Dexamethasone In Part 2, participants received oprozomib IR 150 mg/day on days 1 and 2 of cycle 1, and oprozomib IR 200 mg/day administered orally every week on 2 consecutive days from cycle 1 day 8 onwards (2/7 schedule), for up to 10 months. Participants also received dexamethasone 20 mg orally (days 1, 2, 8, 9, 15, 16, 22, and 23 of each 28-day cycle), and pomalidomide 4 mg orally once daily on days 1 to 21 of each 28-day cycle.	Oprozomib GR 200 mg/Day + Pomalidomide + Dexamethasone In Part 2, participants received oprozomib GR 150 mg/day on days 1 and 2 of cycle 1, and oprozomib GR 200 mg/day administered orally every week on 2 consecutive days from cycle 1 day 8 onwards (2/7 schedule), for up to 10 months. Participants also received dexamethasone 20 mg orally (days 1, 2, 8, 9, 15, 16, 22, and 23 of each 28-day cycle), and pomalidomide 4 mg orally once daily on days 1 to 21 of each 28-day cycle.	Oprozomib IR 225 mg/Day + Pomalidomide + Dexamethasone In Part 2, participants received oprozomib IR 150 mg/day on days 1 and 2 of cycle 1, and oprozomib IR 225 mg/day administered orally every week on 2 consecutive days from cycle 1 day 8 onwards (2/7 schedule), for up to 10 months. Participants also received dexamethasone 20 mg orally (days 1, 2, 8, 9, 15, 16, 22, and 23 of each 28-day cycle), and pomalidomide 4 mg orally once daily on days 1 to 21 of each 28-day cycle.	Oprozomib IR 250 mg/Day + Pomalidomide + Dexamethasone In Part 2, participants received oprozomib IR 150 mg/day on days 1 and 2 of cycle 1, and oprozomib IR 250 mg/day administered orally every week on 2 consecutive days from cycle 1 day 8 onwards (2/7 schedule), for up to 10 months. Participants also received dexamethasone 20 mg orally (days 1, 2, 8, 9, 15, 16, 22, and 23 of each 28-day cycle), and pomalidomide 4 mg orally once daily on days 1 to 21 of each 28-day cycle.	Open-label Roll-over Eligible participants who had enrolled on separate Amgen oprozomib studies (2011-001 \[NCT01416428\], 2012-001 \[NCT01832727\], OPZ003 \[NCT01881789\], OPZ007 \[NCT01999335\], and OPZ009 \[NCT02244112\]) and were receiving oprozomib as monotherapy, or a combination of oprozomib with dexamethasone, continued treatment in research centers within the United States only. Participants continued receiving the previous dose/schedule of oprozomib GR formulation until disease progression, death, or unacceptable toxicity.
Overall Study STARTED	5	8	3	5	9	5	11	8	7
Overall Study Received Oprozomib	5	8	3	4	9	5	10	8	7
Overall Study COMPLETED	5	5	2	2	7	3	4	5	1
Overall Study NOT COMPLETED	0	3	1	3	2	2	7	3	6

Reasons for withdrawal

Measure	Oprozomib IR 150 mg/Day + Dexamethsone In Part 1, participants received oprozomib IR 150 mg/day administered orally every week on 2 consecutive days (2/7 schedule) in combination with dexamethasone 20 mg orally (days 1, 2, 8, 9, 15, 16, 22, and 23 of each 28-day cycle), for up to 10 months.	Oprozomib GR 150 mg/Day + Dexamethasone In Part 1, participants received oprozomib GR 150 mg/day administered orally every week on 2 consecutive days (2/7 schedule) in combination with dexamethasone 20 mg orally (days 1, 2, 8, 9, 15, 16, 22, and 23 of each 28-day cycle), for up to 10 months.	Oprozomib IR 150 mg/Day + Pomalidomide + Dexamethasone In Part 2, participants received oprozomib IR 150 mg/day administered orally every week on 2 consecutive days (2/7 schedule) in combination with dexamethasone 20 mg orally (days 1, 2, 8, 9, 15, 16, 22, and 23 of each 28-day cycle), for up to 10 months. Participants also received pomalidomide 4 mg orally once daily on days 1 to 21 of each 28-day cycle.	Oprozomib GR 150 mg/Day + Pomalidomide + Dexamethasone In Part 2, participants received oprozomib GR 150 mg/day administered orally every week on 2 consecutive days (2/7 schedule) in combination with dexamethasone 20 mg orally (days 1, 2, 8, 9, 15, 16, 22, and 23 of each 28-day cycle), for up to 10 months. Participants also received pomalidomide 4 mg orally once daily on days 1 to 21 of each 28-day cycle.	Oprozomib IR 200 mg/Day + Pomalidomide + Dexamethasone In Part 2, participants received oprozomib IR 150 mg/day on days 1 and 2 of cycle 1, and oprozomib IR 200 mg/day administered orally every week on 2 consecutive days from cycle 1 day 8 onwards (2/7 schedule), for up to 10 months. Participants also received dexamethasone 20 mg orally (days 1, 2, 8, 9, 15, 16, 22, and 23 of each 28-day cycle), and pomalidomide 4 mg orally once daily on days 1 to 21 of each 28-day cycle.	Oprozomib GR 200 mg/Day + Pomalidomide + Dexamethasone In Part 2, participants received oprozomib GR 150 mg/day on days 1 and 2 of cycle 1, and oprozomib GR 200 mg/day administered orally every week on 2 consecutive days from cycle 1 day 8 onwards (2/7 schedule), for up to 10 months. Participants also received dexamethasone 20 mg orally (days 1, 2, 8, 9, 15, 16, 22, and 23 of each 28-day cycle), and pomalidomide 4 mg orally once daily on days 1 to 21 of each 28-day cycle.	Oprozomib IR 225 mg/Day + Pomalidomide + Dexamethasone In Part 2, participants received oprozomib IR 150 mg/day on days 1 and 2 of cycle 1, and oprozomib IR 225 mg/day administered orally every week on 2 consecutive days from cycle 1 day 8 onwards (2/7 schedule), for up to 10 months. Participants also received dexamethasone 20 mg orally (days 1, 2, 8, 9, 15, 16, 22, and 23 of each 28-day cycle), and pomalidomide 4 mg orally once daily on days 1 to 21 of each 28-day cycle.	Oprozomib IR 250 mg/Day + Pomalidomide + Dexamethasone In Part 2, participants received oprozomib IR 150 mg/day on days 1 and 2 of cycle 1, and oprozomib IR 250 mg/day administered orally every week on 2 consecutive days from cycle 1 day 8 onwards (2/7 schedule), for up to 10 months. Participants also received dexamethasone 20 mg orally (days 1, 2, 8, 9, 15, 16, 22, and 23 of each 28-day cycle), and pomalidomide 4 mg orally once daily on days 1 to 21 of each 28-day cycle.	Open-label Roll-over Eligible participants who had enrolled on separate Amgen oprozomib studies (2011-001 \[NCT01416428\], 2012-001 \[NCT01832727\], OPZ003 \[NCT01881789\], OPZ007 \[NCT01999335\], and OPZ009 \[NCT02244112\]) and were receiving oprozomib as monotherapy, or a combination of oprozomib with dexamethasone, continued treatment in research centers within the United States only. Participants continued receiving the previous dose/schedule of oprozomib GR formulation until disease progression, death, or unacceptable toxicity.
Overall Study Death	0	0	1	0	0	2	1	0	0
Overall Study Sponsor decision	0	1	0	1	2	0	3	1	4
Overall Study Withdrawal by Subject	0	2	0	1	0	0	2	2	2
Overall Study Not treated due to adverse event	0	0	0	1	0	0	1	0	0

Baseline Characteristics

Phase 1b Study Evaluating OPomD in Relapsed or Refractory Multiple Myeloma

Baseline characteristics by cohort

Measure	Oprozomib IR 150 mg/Day + Dexamethsone n=5 Participants In Part 1, participants received oprozomib IR 150 mg/day administered orally every week on 2 consecutive days (2/7 schedule) in combination with dexamethasone 20 mg orally (days 1, 2, 8, 9, 15, 16, 22, and 23 of each 28-day cycle), for up to 10 months.	Oprozomib GR 150 mg/Day + Dexamethasone n=8 Participants In Part 1, participants received oprozomib GR 150 mg/day administered orally every week on 2 consecutive days (2/7 schedule) in combination with dexamethasone 20 mg orally (days 1, 2, 8, 9, 15, 16, 22, and 23 of each 28-day cycle), for up to 10 months.	Oprozomib IR 150 mg/Day + Pomalidomide + Dexamethasone n=4 Participants In Part 2, participants received oprozomib IR 150 mg/day administered orally every week on 2 consecutive days (2/7 schedule) in combination with dexamethasone 20 mg orally (days 1, 2, 8, 9, 15, 16, 22, and 23 of each 28-day cycle), for up to 10 months. Participants also received pomalidomide 4 mg orally once daily on days 1 to 21 of each 28-day cycle.	Oprozomib GR 150 mg/Day + Pomalidomide + Dexamethasone n=4 Participants In Part 2, participants received oprozomib GR 150 mg/day administered orally every week on 2 consecutive days (2/7 schedule) in combination with dexamethasone 20 mg orally (days 1, 2, 8, 9, 15, 16, 22, and 23 of each 28-day cycle), for up to 10 months. Participants also received pomalidomide 4 mg orally once daily on days 1 to 21 of each 28-day cycle.	Oprozomib IR 200 mg/Day + Pomalidomide + Dexamethasone n=8 Participants In Part 2, participants received oprozomib IR 150 mg/day on days 1 and 2 of cycle 1, and oprozomib IR 200 mg/day administered orally every week on 2 consecutive days from cycle 1 day 8 onwards (2/7 schedule), for up to 10 months. Participants also received dexamethasone 20 mg orally (days 1, 2, 8, 9, 15, 16, 22, and 23 of each 28-day cycle), and pomalidomide 4 mg orally once daily on days 1 to 21 of each 28-day cycle.	Oprozomib GR 200 mg/Day + Pomalidomide + Dexamethasone n=5 Participants In Part 2, participants received oprozomib GR 150 mg/day on days 1 and 2 of cycle 1, and oprozomib GR 200 mg/day administered orally every week on 2 consecutive days from cycle 1 day 8 onwards (2/7 schedule), for up to 10 months. Participants also received dexamethasone 20 mg orally (days 1, 2, 8, 9, 15, 16, 22, and 23 of each 28-day cycle), and pomalidomide 4 mg orally once daily on days 1 to 21 of each 28-day cycle.	Oprozomib IR 225 mg/Day + Pomalidomide + Dexamethasone n=10 Participants In Part 2, participants received oprozomib IR 150 mg/day on days 1 and 2 of cycle 1, and oprozomib IR 225 mg/day administered orally every week on 2 consecutive days from cycle 1 day 8 onwards (2/7 schedule), for up to 10 months. Participants also received dexamethasone 20 mg orally (days 1, 2, 8, 9, 15, 16, 22, and 23 of each 28-day cycle), and pomalidomide 4 mg orally once daily on days 1 to 21 of each 28-day cycle.	Oprozomib IR 250 mg/Day + Pomalidomide + Dexamethasone n=8 Participants In Part 2, participants received oprozomib IR 150 mg/day on days 1 and 2 of cycle 1, and oprozomib IR 250 mg/day administered orally every week on 2 consecutive days from cycle 1 day 8 onwards (2/7 schedule), for up to 10 months. Participants also received dexamethasone 20 mg orally (days 1, 2, 8, 9, 15, 16, 22, and 23 of each 28-day cycle), and pomalidomide 4 mg orally once daily on days 1 to 21 of each 28-day cycle.	Open-label Roll-over n=7 Participants Eligible participants who had enrolled on separate Amgen oprozomib studies (2011-001 \[NCT01416428\], 2012-001 \[NCT01832727\], OPZ003 \[NCT01881789\], OPZ007 \[NCT01999335\], and OPZ009 \[NCT02244112\]) and were receiving oprozomib as monotherapy, or a combination of oprozomib with dexamethasone, continued treatment in research centers within the United States only. Participants continued receiving the previous dose/schedule of oprozomib GR formulation until disease progression, death, or unacceptable toxicity.	Total n=59 Participants Total of all reporting groups
Age, Continuous	69.0 years STANDARD_DEVIATION 17.2 • n=5 Participants	59.6 years STANDARD_DEVIATION 8.1 • n=7 Participants	62.5 years STANDARD_DEVIATION 8.7 • n=5 Participants	63.5 years STANDARD_DEVIATION 5.9 • n=4 Participants	64.3 years STANDARD_DEVIATION 9.8 • n=21 Participants	62.0 years STANDARD_DEVIATION 8.2 • n=8 Participants	63.1 years STANDARD_DEVIATION 10.2 • n=8 Participants	65.9 years STANDARD_DEVIATION 10.5 • n=24 Participants	70.4 years STANDARD_DEVIATION 8.7 • n=42 Participants	63.6 years STANDARD_DEVIATION 9.9 • n=42 Participants
Sex: Female, Male Female	1 Participants n=5 Participants	4 Participants n=7 Participants	2 Participants n=5 Participants	1 Participants n=4 Participants	3 Participants n=21 Participants	3 Participants n=8 Participants	3 Participants n=8 Participants	1 Participants n=24 Participants	1 Participants n=42 Participants	19 Participants n=42 Participants
Sex: Female, Male Male	4 Participants n=5 Participants	4 Participants n=7 Participants	2 Participants n=5 Participants	3 Participants n=4 Participants	5 Participants n=21 Participants	2 Participants n=8 Participants	7 Participants n=8 Participants	7 Participants n=24 Participants	6 Participants n=42 Participants	40 Participants n=42 Participants
Ethnicity (NIH/OMB) Hispanic or Latino	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	0 Participants n=8 Participants	0 Participants n=8 Participants	0 Participants n=24 Participants	0 Participants n=42 Participants	0 Participants n=42 Participants
Ethnicity (NIH/OMB) Not Hispanic or Latino	5 Participants n=5 Participants	8 Participants n=7 Participants	4 Participants n=5 Participants	4 Participants n=4 Participants	8 Participants n=21 Participants	5 Participants n=8 Participants	7 Participants n=8 Participants	8 Participants n=24 Participants	7 Participants n=42 Participants	56 Participants n=42 Participants
Ethnicity (NIH/OMB) Unknown or Not Reported	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	0 Participants n=8 Participants	3 Participants n=8 Participants	0 Participants n=24 Participants	0 Participants n=42 Participants	3 Participants n=42 Participants
Race/Ethnicity, Customized Black (or African American)	1 Participants n=5 Participants	1 Participants n=7 Participants	2 Participants n=5 Participants	0 Participants n=4 Participants	1 Participants n=21 Participants	2 Participants n=8 Participants	2 Participants n=8 Participants	1 Participants n=24 Participants	0 Participants n=42 Participants	10 Participants n=42 Participants
Race/Ethnicity, Customized White	4 Participants n=5 Participants	7 Participants n=7 Participants	2 Participants n=5 Participants	4 Participants n=4 Participants	6 Participants n=21 Participants	3 Participants n=8 Participants	7 Participants n=8 Participants	7 Participants n=24 Participants	6 Participants n=42 Participants	46 Participants n=42 Participants
Race/Ethnicity, Customized Other	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	1 Participants n=21 Participants	0 Participants n=8 Participants	1 Participants n=8 Participants	0 Participants n=24 Participants	1 Participants n=42 Participants	3 Participants n=42 Participants

PRIMARY outcome

Timeframe: Day 1 to day 28 of cycle 1, where each cycle was 28 days

Population: DLT-evaluable participants received the following during the 28-day DLT window: all planned doses of oprozomib, a minimum of 17 of 21 planned doses of pomalidomide, and a minimum of 6 of 8 planned doses of dexamethasone. One participant enrolled in arm Oprozomib IR 200 mg/day + pomalidomide + dexamethasone received oprozomib IR 150 mg + pomalidomide + dexamethasone, and this participant was included in the Oprozomib IR 150 mg + pomalidomide + dexamethasone arm.

DLTs were graded using the Common Terminology Criteria for Adverse Events (CTCAE) version 4.03 and included the below, if judged by the investigator/medical monitor to be possibly related to study treatment: Non-hematologic DLTs were any ≥ Grade 3 toxicity, except: Grade 3 asymptomatic electrolyte abnormalities (except hypophosphatemia > 24 hours); Grade 3 nausea, vomiting and diarrhea < 3 days; Grade 3 fatigue < 14 days; ≥ Grade 3 hyperglycemia/toxicity due to dexamethasone; ≥ Grade 3 rash due to pomalidomide. Hematologic DLTs included: Grade 4 neutropenia if absolute neutrophil count < 0.5 x 10^9/L ≥ 7 days; febrile neutropenia; Grade 4 thrombocytopenia ≥ 7 days; Grade ≥ 3 with ≥ Grade 2 bleeding/requiring platelet transfusion.

Outcome measures

Measure	Oprozomib GR 200 mg/Day + Pomalidomide + Dexamethasone n=5 Participants In Part 2, participants received oprozomib GR 150 mg/day on days 1 and 2 of cycle 1, and oprozomib GR 200 mg/day administered orally every week on 2 consecutive days from cycle 1 day 8 onwards (2/7 schedule), for up to 10 months. Participants also received dexamethasone 20 mg orally (days 1, 2, 8, 9, 15, 16, 22, and 23 of each 28-day cycle), and pomalidomide 4 mg orally once daily on days 1 to 21 of each 28-day cycle.	Oprozomib IR 150 mg/Day + Dexamethsone n=5 Participants In Part 1, participants received oprozomib IR 150 mg/day administered orally every week on 2 consecutive days (2/7 schedule) in combination with dexamethasone 20 mg orally (days 1, 2, 8, 9, 15, 16, 22, and 23 of each 28-day cycle), for up to 10 months.	Oprozomib GR 150 mg/Day + Dexamethasone n=8 Participants In Part 1, participants received oprozomib GR 150 mg/day administered orally every week on 2 consecutive days (2/7 schedule) in combination with dexamethasone 20 mg orally (days 1, 2, 8, 9, 15, 16, 22, and 23 of each 28-day cycle), for up to 10 months.	Oprozomib IR 150 mg/Day + Pomalidomide + Dexamethasone n=4 Participants In Part 2, participants received oprozomib IR 150 mg/day administered orally every week on 2 consecutive days (2/7 schedule) in combination with dexamethasone 20 mg orally (days 1, 2, 8, 9, 15, 16, 22, and 23 of each 28-day cycle), for up to 10 months. Participants also received pomalidomide 4 mg orally once daily on days 1 to 21 of each 28-day cycle.	Oprozomib GR 150 mg/Day + Pomalidomide + Dexamethasone n=4 Participants In Part 2, participants received oprozomib GR 150 mg/day administered orally every week on 2 consecutive days (2/7 schedule) in combination with dexamethasone 20 mg orally (days 1, 2, 8, 9, 15, 16, 22, and 23 of each 28-day cycle), for up to 10 months. Participants also received pomalidomide 4 mg orally once daily on days 1 to 21 of each 28-day cycle.	Oprozomib IR 200 mg/Day + Pomalidomide + Dexamethasone n=8 Participants In Part 2, participants received oprozomib IR 150 mg/day on days 1 and 2 of cycle 1, and oprozomib IR 200 mg/day administered orally every week on 2 consecutive days from cycle 1 day 8 onwards (2/7 schedule), for up to 10 months. Participants also received dexamethasone 20 mg orally (days 1, 2, 8, 9, 15, 16, 22, and 23 of each 28-day cycle), and pomalidomide 4 mg orally once daily on days 1 to 21 of each 28-day cycle.	Oprozomib IR 225 mg/Day + Pomalidomide + Dexamethasone n=10 Participants In Part 2, participants received oprozomib IR 150 mg/day on days 1 and 2 of cycle 1, and oprozomib IR 225 mg/day administered orally every week on 2 consecutive days from cycle 1 day 8 onwards (2/7 schedule), for up to 10 months. Participants also received dexamethasone 20 mg orally (days 1, 2, 8, 9, 15, 16, 22, and 23 of each 28-day cycle), and pomalidomide 4 mg orally once daily on days 1 to 21 of each 28-day cycle.	Oprozomib IR 250 mg/Day + Pomalidomide + Dexamethasone n=8 Participants In Part 2, participants received oprozomib IR 150 mg/day on days 1 and 2 of cycle 1, and oprozomib IR 250 mg/day administered orally every week on 2 consecutive days from cycle 1 day 8 onwards (2/7 schedule), for up to 10 months. Participants also received dexamethasone 20 mg orally (days 1, 2, 8, 9, 15, 16, 22, and 23 of each 28-day cycle), and pomalidomide 4 mg orally once daily on days 1 to 21 of each 28-day cycle.
Number of Participants Who Experienced Dose-Limiting Toxcity (DLT)	1 Participants	0 Participants	0 Participants	1 Participants	1 Participants	1 Participants	0 Participants	2 Participants

PRIMARY outcome

Timeframe: Day 1 to Day 28 of cycle 1, where each cycle was 28 days

Population: DLT-evaluable participants in Part 2 who received the following during the 28-day DLT window: all planned doses of oprozomib, a minimum of 17 of 21 planned doses of pomalidomide, and a minimum of 6 of 8 planned doses of dexamethasone.

The MTD was the dose with the highest posterior probability of having a DLT rate within the target toxicity interval (15% to 25%), while the posterior probability of excessive/unacceptable toxicity (>25% to 100%) is <40%.

DLTs were graded using CTCAE version 4.03 and included the below, if judged by the investigator/medical monitor to be possibly related to study treatment: Non-hematologic DLTs were any ≥ Grade 3 toxicity, except: Grade 3 asymptomatic electrolyte abnormalities (except hypophosphatemia > 24 hours); Grade 3 nausea, vomiting and diarrhea < 3 days; Grade 3 fatigue < 14 days; ≥ Grade 3 hyperglycemia/toxicity due to dexamethasone; ≥ Grade 3 rash due to pomalidomide. Hematologic DLTs included: Grade 4 neutropenia if absolute neutrophil count < 0.5 x 10^9/L ≥ 7 days; febrile neutropenia; Grade 4 thrombocytopenia ≥ 7 days; Grade ≥ 3 with ≥ Grade 2 bleeding/requiring platelet transfusion.

Outcome measures

Measure	Oprozomib GR 200 mg/Day + Pomalidomide + Dexamethasone In Part 2, participants received oprozomib GR 150 mg/day on days 1 and 2 of cycle 1, and oprozomib GR 200 mg/day administered orally every week on 2 consecutive days from cycle 1 day 8 onwards (2/7 schedule), for up to 10 months. Participants also received dexamethasone 20 mg orally (days 1, 2, 8, 9, 15, 16, 22, and 23 of each 28-day cycle), and pomalidomide 4 mg orally once daily on days 1 to 21 of each 28-day cycle.	Oprozomib IR 150 mg/Day + Dexamethsone n=30 Participants In Part 1, participants received oprozomib IR 150 mg/day administered orally every week on 2 consecutive days (2/7 schedule) in combination with dexamethasone 20 mg orally (days 1, 2, 8, 9, 15, 16, 22, and 23 of each 28-day cycle), for up to 10 months.	Oprozomib GR 150 mg/Day + Dexamethasone n=9 Participants In Part 1, participants received oprozomib GR 150 mg/day administered orally every week on 2 consecutive days (2/7 schedule) in combination with dexamethasone 20 mg orally (days 1, 2, 8, 9, 15, 16, 22, and 23 of each 28-day cycle), for up to 10 months.	Oprozomib IR 150 mg/Day + Pomalidomide + Dexamethasone In Part 2, participants received oprozomib IR 150 mg/day administered orally every week on 2 consecutive days (2/7 schedule) in combination with dexamethasone 20 mg orally (days 1, 2, 8, 9, 15, 16, 22, and 23 of each 28-day cycle), for up to 10 months. Participants also received pomalidomide 4 mg orally once daily on days 1 to 21 of each 28-day cycle.	Oprozomib GR 150 mg/Day + Pomalidomide + Dexamethasone In Part 2, participants received oprozomib GR 150 mg/day administered orally every week on 2 consecutive days (2/7 schedule) in combination with dexamethasone 20 mg orally (days 1, 2, 8, 9, 15, 16, 22, and 23 of each 28-day cycle), for up to 10 months. Participants also received pomalidomide 4 mg orally once daily on days 1 to 21 of each 28-day cycle.	Oprozomib IR 200 mg/Day + Pomalidomide + Dexamethasone In Part 2, participants received oprozomib IR 150 mg/day on days 1 and 2 of cycle 1, and oprozomib IR 200 mg/day administered orally every week on 2 consecutive days from cycle 1 day 8 onwards (2/7 schedule), for up to 10 months. Participants also received dexamethasone 20 mg orally (days 1, 2, 8, 9, 15, 16, 22, and 23 of each 28-day cycle), and pomalidomide 4 mg orally once daily on days 1 to 21 of each 28-day cycle.	Oprozomib IR 225 mg/Day + Pomalidomide + Dexamethasone In Part 2, participants received oprozomib IR 150 mg/day on days 1 and 2 of cycle 1, and oprozomib IR 225 mg/day administered orally every week on 2 consecutive days from cycle 1 day 8 onwards (2/7 schedule), for up to 10 months. Participants also received dexamethasone 20 mg orally (days 1, 2, 8, 9, 15, 16, 22, and 23 of each 28-day cycle), and pomalidomide 4 mg orally once daily on days 1 to 21 of each 28-day cycle.	Oprozomib IR 250 mg/Day + Pomalidomide + Dexamethasone In Part 2, participants received oprozomib IR 150 mg/day on days 1 and 2 of cycle 1, and oprozomib IR 250 mg/day administered orally every week on 2 consecutive days from cycle 1 day 8 onwards (2/7 schedule), for up to 10 months. Participants also received dexamethasone 20 mg orally (days 1, 2, 8, 9, 15, 16, 22, and 23 of each 28-day cycle), and pomalidomide 4 mg orally once daily on days 1 to 21 of each 28-day cycle.
Maximum Tolerated Dose (MTD) of Each Formulation of Oprozomib in Combination With Pomolidomide and Dexamethasone	—	250 mg/day	NA mg/day The MTD for oprozomib GR in combination with pomalidomide and dexamethasone was not determined due to too few DLTs.	—	—	—	—	—

PRIMARY outcome

Timeframe: Day 1 of cycle 1 to 30 (+7) days after the last dose of study treatment or end of study date, whichever is earlier (where each cycle was 28 days). Median treatment duration in Part 1 was 11.43 weeks and in Part 2 was 28 weeks

Population: Participants in the safety analysis set who received any amount of oprozomib, pomalidomide and/or dexamethasone in Parts 1 and 2.

An adverse event (AE) is defined as any untoward medical occurrence in a clinical trial participant. TEAEs were any AE that started on or after receiving the first dose of investigational product and up to and including 30 days after the last dose of investigational product or the end of study date, whichever is earlier. Treatment-related TEAEs were those considered related to study treatment by the investigator. Any clinically significant changes in electrocardiograms, vital signs, physical examination with a neurological assessment and clinical laboratory tests were recorded as TEAEs.

Outcome measures

Measure	Oprozomib GR 200 mg/Day + Pomalidomide + Dexamethasone n=5 Participants In Part 2, participants received oprozomib GR 150 mg/day on days 1 and 2 of cycle 1, and oprozomib GR 200 mg/day administered orally every week on 2 consecutive days from cycle 1 day 8 onwards (2/7 schedule), for up to 10 months. Participants also received dexamethasone 20 mg orally (days 1, 2, 8, 9, 15, 16, 22, and 23 of each 28-day cycle), and pomalidomide 4 mg orally once daily on days 1 to 21 of each 28-day cycle.	Oprozomib IR 150 mg/Day + Dexamethsone n=5 Participants In Part 1, participants received oprozomib IR 150 mg/day administered orally every week on 2 consecutive days (2/7 schedule) in combination with dexamethasone 20 mg orally (days 1, 2, 8, 9, 15, 16, 22, and 23 of each 28-day cycle), for up to 10 months.	Oprozomib GR 150 mg/Day + Dexamethasone n=8 Participants In Part 1, participants received oprozomib GR 150 mg/day administered orally every week on 2 consecutive days (2/7 schedule) in combination with dexamethasone 20 mg orally (days 1, 2, 8, 9, 15, 16, 22, and 23 of each 28-day cycle), for up to 10 months.	Oprozomib IR 150 mg/Day + Pomalidomide + Dexamethasone n=4 Participants In Part 2, participants received oprozomib IR 150 mg/day administered orally every week on 2 consecutive days (2/7 schedule) in combination with dexamethasone 20 mg orally (days 1, 2, 8, 9, 15, 16, 22, and 23 of each 28-day cycle), for up to 10 months. Participants also received pomalidomide 4 mg orally once daily on days 1 to 21 of each 28-day cycle.	Oprozomib GR 150 mg/Day + Pomalidomide + Dexamethasone n=4 Participants In Part 2, participants received oprozomib GR 150 mg/day administered orally every week on 2 consecutive days (2/7 schedule) in combination with dexamethasone 20 mg orally (days 1, 2, 8, 9, 15, 16, 22, and 23 of each 28-day cycle), for up to 10 months. Participants also received pomalidomide 4 mg orally once daily on days 1 to 21 of each 28-day cycle.	Oprozomib IR 200 mg/Day + Pomalidomide + Dexamethasone n=8 Participants In Part 2, participants received oprozomib IR 150 mg/day on days 1 and 2 of cycle 1, and oprozomib IR 200 mg/day administered orally every week on 2 consecutive days from cycle 1 day 8 onwards (2/7 schedule), for up to 10 months. Participants also received dexamethasone 20 mg orally (days 1, 2, 8, 9, 15, 16, 22, and 23 of each 28-day cycle), and pomalidomide 4 mg orally once daily on days 1 to 21 of each 28-day cycle.	Oprozomib IR 225 mg/Day + Pomalidomide + Dexamethasone n=10 Participants In Part 2, participants received oprozomib IR 150 mg/day on days 1 and 2 of cycle 1, and oprozomib IR 225 mg/day administered orally every week on 2 consecutive days from cycle 1 day 8 onwards (2/7 schedule), for up to 10 months. Participants also received dexamethasone 20 mg orally (days 1, 2, 8, 9, 15, 16, 22, and 23 of each 28-day cycle), and pomalidomide 4 mg orally once daily on days 1 to 21 of each 28-day cycle.	Oprozomib IR 250 mg/Day + Pomalidomide + Dexamethasone n=8 Participants In Part 2, participants received oprozomib IR 150 mg/day on days 1 and 2 of cycle 1, and oprozomib IR 250 mg/day administered orally every week on 2 consecutive days from cycle 1 day 8 onwards (2/7 schedule), for up to 10 months. Participants also received dexamethasone 20 mg orally (days 1, 2, 8, 9, 15, 16, 22, and 23 of each 28-day cycle), and pomalidomide 4 mg orally once daily on days 1 to 21 of each 28-day cycle.
Number of Participants With Treatment-emergent Adverse Events (TEAEs) (Oprozomib in Combination With Dexamethasone and/or Pomalidomide) Any TEAE	5 Participants	4 Participants	8 Participants	4 Participants	4 Participants	8 Participants	10 Participants	8 Participants
Number of Participants With Treatment-emergent Adverse Events (TEAEs) (Oprozomib in Combination With Dexamethasone and/or Pomalidomide) Any Treatment-related TEAE	5 Participants	4 Participants	8 Participants	4 Participants	4 Participants	8 Participants	10 Participants	8 Participants

PRIMARY outcome

Timeframe: Day 1 to 30 (+7) days after the last dose of study treatment or end of study date, whichever is earlier (where each cycle was 28 days). Median treatment duration for the open-label roll-over arm was 75.14 weeks

Population: The safety analysis set for roll-over participants included all roll-over participants who received any amount of oprozomib, pomalidomide and/or dexamethasone. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.

TEAEs were any AE that started on or after receiving the first dose of investigational product and up to and including 30 days after the last dose of investigational product or the end of study date, whichever is earlier. Treatment-related TEAEs were those considered related to study treatment by the investigator. Serious TEAEs were any AE meeting at least 1 of the following criteria: fatal; life-threatening; required in-patient hospitalization or prolongation of existing hospitalization; resulted in persistent or significant disability/incapacity; congenital anomaly/birth defect; other medically important serious event.

Outcome measures

Measure	Oprozomib GR 200 mg/Day + Pomalidomide + Dexamethasone In Part 2, participants received oprozomib GR 150 mg/day on days 1 and 2 of cycle 1, and oprozomib GR 200 mg/day administered orally every week on 2 consecutive days from cycle 1 day 8 onwards (2/7 schedule), for up to 10 months. Participants also received dexamethasone 20 mg orally (days 1, 2, 8, 9, 15, 16, 22, and 23 of each 28-day cycle), and pomalidomide 4 mg orally once daily on days 1 to 21 of each 28-day cycle.	Oprozomib IR 150 mg/Day + Dexamethsone n=7 Participants In Part 1, participants received oprozomib IR 150 mg/day administered orally every week on 2 consecutive days (2/7 schedule) in combination with dexamethasone 20 mg orally (days 1, 2, 8, 9, 15, 16, 22, and 23 of each 28-day cycle), for up to 10 months.	Oprozomib GR 150 mg/Day + Dexamethasone In Part 1, participants received oprozomib GR 150 mg/day administered orally every week on 2 consecutive days (2/7 schedule) in combination with dexamethasone 20 mg orally (days 1, 2, 8, 9, 15, 16, 22, and 23 of each 28-day cycle), for up to 10 months.	Oprozomib IR 150 mg/Day + Pomalidomide + Dexamethasone In Part 2, participants received oprozomib IR 150 mg/day administered orally every week on 2 consecutive days (2/7 schedule) in combination with dexamethasone 20 mg orally (days 1, 2, 8, 9, 15, 16, 22, and 23 of each 28-day cycle), for up to 10 months. Participants also received pomalidomide 4 mg orally once daily on days 1 to 21 of each 28-day cycle.	Oprozomib GR 150 mg/Day + Pomalidomide + Dexamethasone In Part 2, participants received oprozomib GR 150 mg/day administered orally every week on 2 consecutive days (2/7 schedule) in combination with dexamethasone 20 mg orally (days 1, 2, 8, 9, 15, 16, 22, and 23 of each 28-day cycle), for up to 10 months. Participants also received pomalidomide 4 mg orally once daily on days 1 to 21 of each 28-day cycle.	Oprozomib IR 200 mg/Day + Pomalidomide + Dexamethasone In Part 2, participants received oprozomib IR 150 mg/day on days 1 and 2 of cycle 1, and oprozomib IR 200 mg/day administered orally every week on 2 consecutive days from cycle 1 day 8 onwards (2/7 schedule), for up to 10 months. Participants also received dexamethasone 20 mg orally (days 1, 2, 8, 9, 15, 16, 22, and 23 of each 28-day cycle), and pomalidomide 4 mg orally once daily on days 1 to 21 of each 28-day cycle.	Oprozomib IR 225 mg/Day + Pomalidomide + Dexamethasone In Part 2, participants received oprozomib IR 150 mg/day on days 1 and 2 of cycle 1, and oprozomib IR 225 mg/day administered orally every week on 2 consecutive days from cycle 1 day 8 onwards (2/7 schedule), for up to 10 months. Participants also received dexamethasone 20 mg orally (days 1, 2, 8, 9, 15, 16, 22, and 23 of each 28-day cycle), and pomalidomide 4 mg orally once daily on days 1 to 21 of each 28-day cycle.	Oprozomib IR 250 mg/Day + Pomalidomide + Dexamethasone In Part 2, participants received oprozomib IR 150 mg/day on days 1 and 2 of cycle 1, and oprozomib IR 250 mg/day administered orally every week on 2 consecutive days from cycle 1 day 8 onwards (2/7 schedule), for up to 10 months. Participants also received dexamethasone 20 mg orally (days 1, 2, 8, 9, 15, 16, 22, and 23 of each 28-day cycle), and pomalidomide 4 mg orally once daily on days 1 to 21 of each 28-day cycle.
Number of Participants With TEAEs and Treatment-emergent Serious AEs (Open-label Roll-over) Any TEAE	—	7 Participants	—	—	—	—	—	—
Number of Participants With TEAEs and Treatment-emergent Serious AEs (Open-label Roll-over) Any Serious TEAE	—	4 Participants	—	—	—	—	—	—

SECONDARY outcome

Timeframe: Cycle 1 days 8 and 22: pre-dose, 0.5, 1, 2, 4, and 6 hours post-dose. GR only: cycle 1 day 8: 8 hours post-dose

Population: Participants in the PK analysis set with data available at each time point. The PK analysis set included participants for whom at least 1 PK parameter could be adequately estimated, excluding roll-over participants.

The mean Cmax of oprozomib is presented following dosing on cycle 1 day 8 and cycle 1 day 22 for the IR and GR oprozomib formulations.

Outcome measures

Measure	Oprozomib GR 200 mg/Day + Pomalidomide + Dexamethasone n=5 Participants In Part 2, participants received oprozomib GR 150 mg/day on days 1 and 2 of cycle 1, and oprozomib GR 200 mg/day administered orally every week on 2 consecutive days from cycle 1 day 8 onwards (2/7 schedule), for up to 10 months. Participants also received dexamethasone 20 mg orally (days 1, 2, 8, 9, 15, 16, 22, and 23 of each 28-day cycle), and pomalidomide 4 mg orally once daily on days 1 to 21 of each 28-day cycle.	Oprozomib IR 150 mg/Day + Dexamethsone n=3 Participants In Part 1, participants received oprozomib IR 150 mg/day administered orally every week on 2 consecutive days (2/7 schedule) in combination with dexamethasone 20 mg orally (days 1, 2, 8, 9, 15, 16, 22, and 23 of each 28-day cycle), for up to 10 months.	Oprozomib GR 150 mg/Day + Dexamethasone n=6 Participants In Part 1, participants received oprozomib GR 150 mg/day administered orally every week on 2 consecutive days (2/7 schedule) in combination with dexamethasone 20 mg orally (days 1, 2, 8, 9, 15, 16, 22, and 23 of each 28-day cycle), for up to 10 months.	Oprozomib IR 150 mg/Day + Pomalidomide + Dexamethasone n=3 Participants In Part 2, participants received oprozomib IR 150 mg/day administered orally every week on 2 consecutive days (2/7 schedule) in combination with dexamethasone 20 mg orally (days 1, 2, 8, 9, 15, 16, 22, and 23 of each 28-day cycle), for up to 10 months. Participants also received pomalidomide 4 mg orally once daily on days 1 to 21 of each 28-day cycle.	Oprozomib GR 150 mg/Day + Pomalidomide + Dexamethasone n=3 Participants In Part 2, participants received oprozomib GR 150 mg/day administered orally every week on 2 consecutive days (2/7 schedule) in combination with dexamethasone 20 mg orally (days 1, 2, 8, 9, 15, 16, 22, and 23 of each 28-day cycle), for up to 10 months. Participants also received pomalidomide 4 mg orally once daily on days 1 to 21 of each 28-day cycle.	Oprozomib IR 200 mg/Day + Pomalidomide + Dexamethasone n=7 Participants In Part 2, participants received oprozomib IR 150 mg/day on days 1 and 2 of cycle 1, and oprozomib IR 200 mg/day administered orally every week on 2 consecutive days from cycle 1 day 8 onwards (2/7 schedule), for up to 10 months. Participants also received dexamethasone 20 mg orally (days 1, 2, 8, 9, 15, 16, 22, and 23 of each 28-day cycle), and pomalidomide 4 mg orally once daily on days 1 to 21 of each 28-day cycle.	Oprozomib IR 225 mg/Day + Pomalidomide + Dexamethasone n=10 Participants In Part 2, participants received oprozomib IR 150 mg/day on days 1 and 2 of cycle 1, and oprozomib IR 225 mg/day administered orally every week on 2 consecutive days from cycle 1 day 8 onwards (2/7 schedule), for up to 10 months. Participants also received dexamethasone 20 mg orally (days 1, 2, 8, 9, 15, 16, 22, and 23 of each 28-day cycle), and pomalidomide 4 mg orally once daily on days 1 to 21 of each 28-day cycle.	Oprozomib IR 250 mg/Day + Pomalidomide + Dexamethasone n=7 Participants In Part 2, participants received oprozomib IR 150 mg/day on days 1 and 2 of cycle 1, and oprozomib IR 250 mg/day administered orally every week on 2 consecutive days from cycle 1 day 8 onwards (2/7 schedule), for up to 10 months. Participants also received dexamethasone 20 mg orally (days 1, 2, 8, 9, 15, 16, 22, and 23 of each 28-day cycle), and pomalidomide 4 mg orally once daily on days 1 to 21 of each 28-day cycle.
Maximum Observed Concentration (Cmax) of Oprozomib Cycle 1 Day 22	137 ng/mL Standard Deviation 81.1	453 ng/mL Standard Deviation 48.0	209 ng/mL Standard Deviation 185	305 ng/mL Standard Deviation NA Standard deviation (SD) could not be determined due to too few participants with available data at this time point.	191 ng/mL Standard Deviation 99.2	1040 ng/mL Standard Deviation 941	1580 ng/mL Standard Deviation 672	1420 ng/mL Standard Deviation 1250
Maximum Observed Concentration (Cmax) of Oprozomib Cycle 1 Day 8	367 ng/mL Standard Deviation 429	321 ng/mL Standard Deviation 89.2	118 ng/mL Standard Deviation 90.3	349 ng/mL Standard Deviation 195	119 ng/mL Standard Deviation 77.7	694 ng/mL Standard Deviation 479	1020 ng/mL Standard Deviation 911	800 ng/mL Standard Deviation 703

SECONDARY outcome

Timeframe: Cycle 1 days 8 and 22: pre-dose, 0.5, 1, 2, 4, and 6 hours post-dose. GR only: cycle 1 day 8: 8 hours post-dose

Population: Participants in the PK analysis set with data available at each time point. The PK analysis set included participants for whom at least 1 PK parameter could be adequately estimated, excluding roll-over participants.

The median Tmax of oprozomib is presented following dosing on cycle 1 day 8 and cycle 1 day 22 for the IR and GR oprozomib formulations.

Outcome measures

Measure	Oprozomib GR 200 mg/Day + Pomalidomide + Dexamethasone n=5 Participants In Part 2, participants received oprozomib GR 150 mg/day on days 1 and 2 of cycle 1, and oprozomib GR 200 mg/day administered orally every week on 2 consecutive days from cycle 1 day 8 onwards (2/7 schedule), for up to 10 months. Participants also received dexamethasone 20 mg orally (days 1, 2, 8, 9, 15, 16, 22, and 23 of each 28-day cycle), and pomalidomide 4 mg orally once daily on days 1 to 21 of each 28-day cycle.	Oprozomib IR 150 mg/Day + Dexamethsone n=3 Participants In Part 1, participants received oprozomib IR 150 mg/day administered orally every week on 2 consecutive days (2/7 schedule) in combination with dexamethasone 20 mg orally (days 1, 2, 8, 9, 15, 16, 22, and 23 of each 28-day cycle), for up to 10 months.	Oprozomib GR 150 mg/Day + Dexamethasone n=6 Participants In Part 1, participants received oprozomib GR 150 mg/day administered orally every week on 2 consecutive days (2/7 schedule) in combination with dexamethasone 20 mg orally (days 1, 2, 8, 9, 15, 16, 22, and 23 of each 28-day cycle), for up to 10 months.	Oprozomib IR 150 mg/Day + Pomalidomide + Dexamethasone n=3 Participants In Part 2, participants received oprozomib IR 150 mg/day administered orally every week on 2 consecutive days (2/7 schedule) in combination with dexamethasone 20 mg orally (days 1, 2, 8, 9, 15, 16, 22, and 23 of each 28-day cycle), for up to 10 months. Participants also received pomalidomide 4 mg orally once daily on days 1 to 21 of each 28-day cycle.	Oprozomib GR 150 mg/Day + Pomalidomide + Dexamethasone n=3 Participants In Part 2, participants received oprozomib GR 150 mg/day administered orally every week on 2 consecutive days (2/7 schedule) in combination with dexamethasone 20 mg orally (days 1, 2, 8, 9, 15, 16, 22, and 23 of each 28-day cycle), for up to 10 months. Participants also received pomalidomide 4 mg orally once daily on days 1 to 21 of each 28-day cycle.	Oprozomib IR 200 mg/Day + Pomalidomide + Dexamethasone n=7 Participants In Part 2, participants received oprozomib IR 150 mg/day on days 1 and 2 of cycle 1, and oprozomib IR 200 mg/day administered orally every week on 2 consecutive days from cycle 1 day 8 onwards (2/7 schedule), for up to 10 months. Participants also received dexamethasone 20 mg orally (days 1, 2, 8, 9, 15, 16, 22, and 23 of each 28-day cycle), and pomalidomide 4 mg orally once daily on days 1 to 21 of each 28-day cycle.	Oprozomib IR 225 mg/Day + Pomalidomide + Dexamethasone n=10 Participants In Part 2, participants received oprozomib IR 150 mg/day on days 1 and 2 of cycle 1, and oprozomib IR 225 mg/day administered orally every week on 2 consecutive days from cycle 1 day 8 onwards (2/7 schedule), for up to 10 months. Participants also received dexamethasone 20 mg orally (days 1, 2, 8, 9, 15, 16, 22, and 23 of each 28-day cycle), and pomalidomide 4 mg orally once daily on days 1 to 21 of each 28-day cycle.	Oprozomib IR 250 mg/Day + Pomalidomide + Dexamethasone n=7 Participants In Part 2, participants received oprozomib IR 150 mg/day on days 1 and 2 of cycle 1, and oprozomib IR 250 mg/day administered orally every week on 2 consecutive days from cycle 1 day 8 onwards (2/7 schedule), for up to 10 months. Participants also received dexamethasone 20 mg orally (days 1, 2, 8, 9, 15, 16, 22, and 23 of each 28-day cycle), and pomalidomide 4 mg orally once daily on days 1 to 21 of each 28-day cycle.
Time to Cmax (Tmax) of Oprozomib Cycle 1 Day 8	2.0 hours Interval 1.1 to 5.8	1.0 hours Interval 0.93 to 1.9	2.0 hours Interval 2.0 to 4.0	2.0 hours Interval 0.5 to 2.0	5.8 hours Interval 3.9 to 6.0	2.0 hours Interval 0.45 to 6.0	1.5 hours Interval 0.47 to 4.2	1.3 hours Interval 0.42 to 5.8
Time to Cmax (Tmax) of Oprozomib Cycle 1 Day 22	4.8 hours Interval 2.0 to 6.0	1.0 hours Interval 0.98 to 2.0	3.0 hours Interval 1.9 to 6.0	1.0 hours Interval 1.0 to 1.0	4.1 hours Interval 3.7 to 6.0	1.3 hours Interval 0.45 to 2.0	0.98 hours Interval 0.42 to 2.2	0.75 hours Interval 0.5 to 1.1

SECONDARY outcome

Timeframe: Cycle 1 days 8 and 22: pre-dose, 0.5, 1, 2, 4, and 6 hours post-dose. GR only: cycle 1 day 8: 8 hours post-dose

Population: Participants in the PK analysis set with data available at each time point. The PK analysis set included participants for whom at least 1 PK parameter could be adequately estimated, excluding roll-over participants.

The mean AUClast of oprozomib is presented following dosing on cycle 1 day 8 and cycle 1 day 22 for the IR and GR oprozomib formulations.

Outcome measures

Measure	Oprozomib GR 200 mg/Day + Pomalidomide + Dexamethasone n=5 Participants In Part 2, participants received oprozomib GR 150 mg/day on days 1 and 2 of cycle 1, and oprozomib GR 200 mg/day administered orally every week on 2 consecutive days from cycle 1 day 8 onwards (2/7 schedule), for up to 10 months. Participants also received dexamethasone 20 mg orally (days 1, 2, 8, 9, 15, 16, 22, and 23 of each 28-day cycle), and pomalidomide 4 mg orally once daily on days 1 to 21 of each 28-day cycle.	Oprozomib IR 150 mg/Day + Dexamethsone n=3 Participants In Part 1, participants received oprozomib IR 150 mg/day administered orally every week on 2 consecutive days (2/7 schedule) in combination with dexamethasone 20 mg orally (days 1, 2, 8, 9, 15, 16, 22, and 23 of each 28-day cycle), for up to 10 months.	Oprozomib GR 150 mg/Day + Dexamethasone n=6 Participants In Part 1, participants received oprozomib GR 150 mg/day administered orally every week on 2 consecutive days (2/7 schedule) in combination with dexamethasone 20 mg orally (days 1, 2, 8, 9, 15, 16, 22, and 23 of each 28-day cycle), for up to 10 months.	Oprozomib IR 150 mg/Day + Pomalidomide + Dexamethasone n=3 Participants In Part 2, participants received oprozomib IR 150 mg/day administered orally every week on 2 consecutive days (2/7 schedule) in combination with dexamethasone 20 mg orally (days 1, 2, 8, 9, 15, 16, 22, and 23 of each 28-day cycle), for up to 10 months. Participants also received pomalidomide 4 mg orally once daily on days 1 to 21 of each 28-day cycle.	Oprozomib GR 150 mg/Day + Pomalidomide + Dexamethasone n=3 Participants In Part 2, participants received oprozomib GR 150 mg/day administered orally every week on 2 consecutive days (2/7 schedule) in combination with dexamethasone 20 mg orally (days 1, 2, 8, 9, 15, 16, 22, and 23 of each 28-day cycle), for up to 10 months. Participants also received pomalidomide 4 mg orally once daily on days 1 to 21 of each 28-day cycle.	Oprozomib IR 200 mg/Day + Pomalidomide + Dexamethasone n=7 Participants In Part 2, participants received oprozomib IR 150 mg/day on days 1 and 2 of cycle 1, and oprozomib IR 200 mg/day administered orally every week on 2 consecutive days from cycle 1 day 8 onwards (2/7 schedule), for up to 10 months. Participants also received dexamethasone 20 mg orally (days 1, 2, 8, 9, 15, 16, 22, and 23 of each 28-day cycle), and pomalidomide 4 mg orally once daily on days 1 to 21 of each 28-day cycle.	Oprozomib IR 225 mg/Day + Pomalidomide + Dexamethasone n=10 Participants In Part 2, participants received oprozomib IR 150 mg/day on days 1 and 2 of cycle 1, and oprozomib IR 225 mg/day administered orally every week on 2 consecutive days from cycle 1 day 8 onwards (2/7 schedule), for up to 10 months. Participants also received dexamethasone 20 mg orally (days 1, 2, 8, 9, 15, 16, 22, and 23 of each 28-day cycle), and pomalidomide 4 mg orally once daily on days 1 to 21 of each 28-day cycle.	Oprozomib IR 250 mg/Day + Pomalidomide + Dexamethasone n=7 Participants In Part 2, participants received oprozomib IR 150 mg/day on days 1 and 2 of cycle 1, and oprozomib IR 250 mg/day administered orally every week on 2 consecutive days from cycle 1 day 8 onwards (2/7 schedule), for up to 10 months. Participants also received dexamethasone 20 mg orally (days 1, 2, 8, 9, 15, 16, 22, and 23 of each 28-day cycle), and pomalidomide 4 mg orally once daily on days 1 to 21 of each 28-day cycle.
Area Under the Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUClast) of Oprozomib Cycle 1 Day 22	888 hour*ng/mL Standard Deviation 1200	1020 hour*ng/mL Standard Deviation 281	1380 hour*ng/mL Standard Deviation 1090	681 hour*ng/mL Standard Deviation NA The SD could not be determined due to too few participants with available data at this time point.	839 hour*ng/mL Standard Deviation 544	1420 hour*ng/mL Standard Deviation 659	2050 hour*ng/mL Standard Deviation 722	2030 hour*ng/mL Standard Deviation 1070
Area Under the Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUClast) of Oprozomib Cycle 1 Day 8	1880 hour*ng/mL Standard Deviation 2190	656 hour*ng/mL Standard Deviation 77.6	357 hour*ng/mL Standard Deviation 252	869 hour*ng/mL Standard Deviation 449	655 hour*ng/mL Standard Deviation 73.5	1210 hour*ng/mL Standard Deviation 658	1730 hour*ng/mL Standard Deviation 1160	1710 hour*ng/mL Standard Deviation 1560

SECONDARY outcome

Timeframe: Day 1 of cycle 1 up to the end of study visit (where each cycle was 28 days); median treatment duration in Part 1 was 11.43 weeks and in Part 2 was 28 weeks

Population: The efficacy analysis set included all participants, excluding roll-over participants, who were included in the safety analysis set, and had a baseline disease assessment and at least 1 post-baseline disease assessment.

BOR was the best response per IMWG-URC from best to worst: stringent complete response (sCR; complete response [CR], normal serum free light chain ratio, no clonal cells in bone marrow [BM]), CR (negative immunofixation on serum and urine, soft tissue plasmacytomas disappearance, < 5% plasma cells in BM), very good partial response (VGPR; serum and urine M-protein detectable by immunofixation or ≥ 90% reduction in serum M-protein [urine M-protein level < 100 mg/24-h]), partial response (PR; ≥ 50% reduction of serum M-protein and 24-h urinary M-protein by ≥ 90% or < 200 mg/24-h), minimal response (MR; 25-49% reduction of serum M-protein and 50-89% in 24-h urinary M-protein, exceeding 200 mg/24-h), stable disease (SD; not CR, VGPR, PR or progressive disease [PD]), and PD (≥ 25% increase in serum or urine M-component, development of new or increased size of existing bone lesions or soft tissue plasmacytomas, hypercalcemia attributed to the plasma cell proliferative disorder).

Outcome measures

Measure	Oprozomib GR 200 mg/Day + Pomalidomide + Dexamethasone n=5 Participants In Part 2, participants received oprozomib GR 150 mg/day on days 1 and 2 of cycle 1, and oprozomib GR 200 mg/day administered orally every week on 2 consecutive days from cycle 1 day 8 onwards (2/7 schedule), for up to 10 months. Participants also received dexamethasone 20 mg orally (days 1, 2, 8, 9, 15, 16, 22, and 23 of each 28-day cycle), and pomalidomide 4 mg orally once daily on days 1 to 21 of each 28-day cycle.	Oprozomib IR 150 mg/Day + Dexamethsone n=3 Participants In Part 1, participants received oprozomib IR 150 mg/day administered orally every week on 2 consecutive days (2/7 schedule) in combination with dexamethasone 20 mg orally (days 1, 2, 8, 9, 15, 16, 22, and 23 of each 28-day cycle), for up to 10 months.	Oprozomib GR 150 mg/Day + Dexamethasone n=6 Participants In Part 1, participants received oprozomib GR 150 mg/day administered orally every week on 2 consecutive days (2/7 schedule) in combination with dexamethasone 20 mg orally (days 1, 2, 8, 9, 15, 16, 22, and 23 of each 28-day cycle), for up to 10 months.	Oprozomib IR 150 mg/Day + Pomalidomide + Dexamethasone n=3 Participants In Part 2, participants received oprozomib IR 150 mg/day administered orally every week on 2 consecutive days (2/7 schedule) in combination with dexamethasone 20 mg orally (days 1, 2, 8, 9, 15, 16, 22, and 23 of each 28-day cycle), for up to 10 months. Participants also received pomalidomide 4 mg orally once daily on days 1 to 21 of each 28-day cycle.	Oprozomib GR 150 mg/Day + Pomalidomide + Dexamethasone n=3 Participants In Part 2, participants received oprozomib GR 150 mg/day administered orally every week on 2 consecutive days (2/7 schedule) in combination with dexamethasone 20 mg orally (days 1, 2, 8, 9, 15, 16, 22, and 23 of each 28-day cycle), for up to 10 months. Participants also received pomalidomide 4 mg orally once daily on days 1 to 21 of each 28-day cycle.	Oprozomib IR 200 mg/Day + Pomalidomide + Dexamethasone n=7 Participants In Part 2, participants received oprozomib IR 150 mg/day on days 1 and 2 of cycle 1, and oprozomib IR 200 mg/day administered orally every week on 2 consecutive days from cycle 1 day 8 onwards (2/7 schedule), for up to 10 months. Participants also received dexamethasone 20 mg orally (days 1, 2, 8, 9, 15, 16, 22, and 23 of each 28-day cycle), and pomalidomide 4 mg orally once daily on days 1 to 21 of each 28-day cycle.	Oprozomib IR 225 mg/Day + Pomalidomide + Dexamethasone n=10 Participants In Part 2, participants received oprozomib IR 150 mg/day on days 1 and 2 of cycle 1, and oprozomib IR 225 mg/day administered orally every week on 2 consecutive days from cycle 1 day 8 onwards (2/7 schedule), for up to 10 months. Participants also received dexamethasone 20 mg orally (days 1, 2, 8, 9, 15, 16, 22, and 23 of each 28-day cycle), and pomalidomide 4 mg orally once daily on days 1 to 21 of each 28-day cycle.	Oprozomib IR 250 mg/Day + Pomalidomide + Dexamethasone n=8 Participants In Part 2, participants received oprozomib IR 150 mg/day on days 1 and 2 of cycle 1, and oprozomib IR 250 mg/day administered orally every week on 2 consecutive days from cycle 1 day 8 onwards (2/7 schedule), for up to 10 months. Participants also received dexamethasone 20 mg orally (days 1, 2, 8, 9, 15, 16, 22, and 23 of each 28-day cycle), and pomalidomide 4 mg orally once daily on days 1 to 21 of each 28-day cycle.
Best Overall Response (BOR) According to Revised International Myeloma Working Group Uniform Response Criteria (IMWG-URC) VGPR	0 Participants	1 Participants	0 Participants	0 Participants	0 Participants	3 Participants	2 Participants	3 Participants
Best Overall Response (BOR) According to Revised International Myeloma Working Group Uniform Response Criteria (IMWG-URC) sCR	1 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	1 Participants	0 Participants
Best Overall Response (BOR) According to Revised International Myeloma Working Group Uniform Response Criteria (IMWG-URC) CR	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	1 Participants
Best Overall Response (BOR) According to Revised International Myeloma Working Group Uniform Response Criteria (IMWG-URC) PR	2 Participants	1 Participants	1 Participants	1 Participants	0 Participants	3 Participants	3 Participants	3 Participants
Best Overall Response (BOR) According to Revised International Myeloma Working Group Uniform Response Criteria (IMWG-URC) MR	0 Participants	0 Participants	0 Participants	2 Participants	1 Participants	0 Participants	0 Participants	0 Participants
Best Overall Response (BOR) According to Revised International Myeloma Working Group Uniform Response Criteria (IMWG-URC) SD	0 Participants	0 Participants	4 Participants	0 Participants	1 Participants	0 Participants	4 Participants	0 Participants
Best Overall Response (BOR) According to Revised International Myeloma Working Group Uniform Response Criteria (IMWG-URC) PD	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants
Best Overall Response (BOR) According to Revised International Myeloma Working Group Uniform Response Criteria (IMWG-URC) Unconfirmed response	2 Participants	1 Participants	1 Participants	0 Participants	1 Participants	1 Participants	0 Participants	1 Participants

SECONDARY outcome

Timeframe: Day 1 of cycle 1 up to the end of study visit (where each cycle was 28 days); median treatment duration in Part 1 was 11.43 weeks and in Part 2 was 28 weeks

Population: The efficacy analysis set included all participants, excluding roll-over participants, who were included in the safety analysis set, and had a baseline disease assessment and at least 1 post-baseline disease assessment.

The ORR was defined as the percentage of participants with a BOR of sCR, CR, VGPR, and PR per the IMWG-URC. Complete response (CR): Negative immunofixation on serum and urine, soft tissue plasmacytomas disappearance, < 5% plasma cells in bone marrow (BM). Stringent CR (sCR): CR and normal serum free light chain ratio and no clonal cells in BM. Very Good Partial Response (VGPR): Serum and urine M-protein detectable by immunofixation or ≥ 90% reduction in serum M-protein (urine M-protein level < 100 mg/24-h). PR: ≥ 50% reduction of serum M-protein and 24-h urinary M-protein by ≥ 90% or to < 200 mg/24-h. The 95% confidence intervals (CIs) were estimated using the Clopper-Pearson method.

Outcome measures

Measure	Oprozomib GR 200 mg/Day + Pomalidomide + Dexamethasone n=5 Participants In Part 2, participants received oprozomib GR 150 mg/day on days 1 and 2 of cycle 1, and oprozomib GR 200 mg/day administered orally every week on 2 consecutive days from cycle 1 day 8 onwards (2/7 schedule), for up to 10 months. Participants also received dexamethasone 20 mg orally (days 1, 2, 8, 9, 15, 16, 22, and 23 of each 28-day cycle), and pomalidomide 4 mg orally once daily on days 1 to 21 of each 28-day cycle.	Oprozomib IR 150 mg/Day + Dexamethsone n=3 Participants In Part 1, participants received oprozomib IR 150 mg/day administered orally every week on 2 consecutive days (2/7 schedule) in combination with dexamethasone 20 mg orally (days 1, 2, 8, 9, 15, 16, 22, and 23 of each 28-day cycle), for up to 10 months.	Oprozomib GR 150 mg/Day + Dexamethasone n=6 Participants In Part 1, participants received oprozomib GR 150 mg/day administered orally every week on 2 consecutive days (2/7 schedule) in combination with dexamethasone 20 mg orally (days 1, 2, 8, 9, 15, 16, 22, and 23 of each 28-day cycle), for up to 10 months.	Oprozomib IR 150 mg/Day + Pomalidomide + Dexamethasone n=3 Participants In Part 2, participants received oprozomib IR 150 mg/day administered orally every week on 2 consecutive days (2/7 schedule) in combination with dexamethasone 20 mg orally (days 1, 2, 8, 9, 15, 16, 22, and 23 of each 28-day cycle), for up to 10 months. Participants also received pomalidomide 4 mg orally once daily on days 1 to 21 of each 28-day cycle.	Oprozomib GR 150 mg/Day + Pomalidomide + Dexamethasone n=3 Participants In Part 2, participants received oprozomib GR 150 mg/day administered orally every week on 2 consecutive days (2/7 schedule) in combination with dexamethasone 20 mg orally (days 1, 2, 8, 9, 15, 16, 22, and 23 of each 28-day cycle), for up to 10 months. Participants also received pomalidomide 4 mg orally once daily on days 1 to 21 of each 28-day cycle.	Oprozomib IR 200 mg/Day + Pomalidomide + Dexamethasone n=7 Participants In Part 2, participants received oprozomib IR 150 mg/day on days 1 and 2 of cycle 1, and oprozomib IR 200 mg/day administered orally every week on 2 consecutive days from cycle 1 day 8 onwards (2/7 schedule), for up to 10 months. Participants also received dexamethasone 20 mg orally (days 1, 2, 8, 9, 15, 16, 22, and 23 of each 28-day cycle), and pomalidomide 4 mg orally once daily on days 1 to 21 of each 28-day cycle.	Oprozomib IR 225 mg/Day + Pomalidomide + Dexamethasone n=10 Participants In Part 2, participants received oprozomib IR 150 mg/day on days 1 and 2 of cycle 1, and oprozomib IR 225 mg/day administered orally every week on 2 consecutive days from cycle 1 day 8 onwards (2/7 schedule), for up to 10 months. Participants also received dexamethasone 20 mg orally (days 1, 2, 8, 9, 15, 16, 22, and 23 of each 28-day cycle), and pomalidomide 4 mg orally once daily on days 1 to 21 of each 28-day cycle.	Oprozomib IR 250 mg/Day + Pomalidomide + Dexamethasone n=8 Participants In Part 2, participants received oprozomib IR 150 mg/day on days 1 and 2 of cycle 1, and oprozomib IR 250 mg/day administered orally every week on 2 consecutive days from cycle 1 day 8 onwards (2/7 schedule), for up to 10 months. Participants also received dexamethasone 20 mg orally (days 1, 2, 8, 9, 15, 16, 22, and 23 of each 28-day cycle), and pomalidomide 4 mg orally once daily on days 1 to 21 of each 28-day cycle.
Overall Response Rate (ORR) According to IMWG-URC	60.0 percentage of participants Interval 14.7 to 94.7	66.7 percentage of participants Interval 9.4 to 99.2	16.7 percentage of participants Interval 0.4 to 64.1	33.3 percentage of participants Interval 0.8 to 90.6	0.0 percentage of participants The 95% CIs could not be determined as no participants achieved OR.	85.7 percentage of participants Interval 42.1 to 99.6	60.0 percentage of participants Interval 26.2 to 87.8	87.5 percentage of participants Interval 47.3 to 99.7

SECONDARY outcome

Timeframe: Day 1 of cycle 1 up to the end of study visit (where each cycle was 28 days); median treatment duration in Part 1 was 11.43 weeks and in Part 2 was 28 weeks

Population: The efficacy analysis set included all participants, excluding roll-over participants, who were included in the safety analysis set, and had a baseline disease assessment and at least 1 post-baseline disease assessment.

PFS was defined as the number of months from a participant's first dose of study treatment to the earlier of disease progression or death due to any cause. The number of participants who had a PFS event or who were censored are presented. PFS events were an assessment of progressive disease according to the IMWG-URC or death due to any cause. PFS data was censored: participants alive and no documented disease progression at time of analysis were censored at date of last disease assessment; participants alive with no disease assessment were censored at the first study dose date; participants alive without documented disease progression, with withdrawn consent were censored at date of last disease assessment before consent withdrawal; and for participants who started anti-cancer therapy other than study treatment prior to documentation of disease progression were censored at date of last disease assessment prior to starting new therapy.

Outcome measures

Measure	Oprozomib GR 200 mg/Day + Pomalidomide + Dexamethasone n=5 Participants In Part 2, participants received oprozomib GR 150 mg/day on days 1 and 2 of cycle 1, and oprozomib GR 200 mg/day administered orally every week on 2 consecutive days from cycle 1 day 8 onwards (2/7 schedule), for up to 10 months. Participants also received dexamethasone 20 mg orally (days 1, 2, 8, 9, 15, 16, 22, and 23 of each 28-day cycle), and pomalidomide 4 mg orally once daily on days 1 to 21 of each 28-day cycle.	Oprozomib IR 150 mg/Day + Dexamethsone n=3 Participants In Part 1, participants received oprozomib IR 150 mg/day administered orally every week on 2 consecutive days (2/7 schedule) in combination with dexamethasone 20 mg orally (days 1, 2, 8, 9, 15, 16, 22, and 23 of each 28-day cycle), for up to 10 months.	Oprozomib GR 150 mg/Day + Dexamethasone n=6 Participants In Part 1, participants received oprozomib GR 150 mg/day administered orally every week on 2 consecutive days (2/7 schedule) in combination with dexamethasone 20 mg orally (days 1, 2, 8, 9, 15, 16, 22, and 23 of each 28-day cycle), for up to 10 months.	Oprozomib IR 150 mg/Day + Pomalidomide + Dexamethasone n=3 Participants In Part 2, participants received oprozomib IR 150 mg/day administered orally every week on 2 consecutive days (2/7 schedule) in combination with dexamethasone 20 mg orally (days 1, 2, 8, 9, 15, 16, 22, and 23 of each 28-day cycle), for up to 10 months. Participants also received pomalidomide 4 mg orally once daily on days 1 to 21 of each 28-day cycle.	Oprozomib GR 150 mg/Day + Pomalidomide + Dexamethasone n=3 Participants In Part 2, participants received oprozomib GR 150 mg/day administered orally every week on 2 consecutive days (2/7 schedule) in combination with dexamethasone 20 mg orally (days 1, 2, 8, 9, 15, 16, 22, and 23 of each 28-day cycle), for up to 10 months. Participants also received pomalidomide 4 mg orally once daily on days 1 to 21 of each 28-day cycle.	Oprozomib IR 200 mg/Day + Pomalidomide + Dexamethasone n=7 Participants In Part 2, participants received oprozomib IR 150 mg/day on days 1 and 2 of cycle 1, and oprozomib IR 200 mg/day administered orally every week on 2 consecutive days from cycle 1 day 8 onwards (2/7 schedule), for up to 10 months. Participants also received dexamethasone 20 mg orally (days 1, 2, 8, 9, 15, 16, 22, and 23 of each 28-day cycle), and pomalidomide 4 mg orally once daily on days 1 to 21 of each 28-day cycle.	Oprozomib IR 225 mg/Day + Pomalidomide + Dexamethasone n=10 Participants In Part 2, participants received oprozomib IR 150 mg/day on days 1 and 2 of cycle 1, and oprozomib IR 225 mg/day administered orally every week on 2 consecutive days from cycle 1 day 8 onwards (2/7 schedule), for up to 10 months. Participants also received dexamethasone 20 mg orally (days 1, 2, 8, 9, 15, 16, 22, and 23 of each 28-day cycle), and pomalidomide 4 mg orally once daily on days 1 to 21 of each 28-day cycle.	Oprozomib IR 250 mg/Day + Pomalidomide + Dexamethasone n=8 Participants In Part 2, participants received oprozomib IR 150 mg/day on days 1 and 2 of cycle 1, and oprozomib IR 250 mg/day administered orally every week on 2 consecutive days from cycle 1 day 8 onwards (2/7 schedule), for up to 10 months. Participants also received dexamethasone 20 mg orally (days 1, 2, 8, 9, 15, 16, 22, and 23 of each 28-day cycle), and pomalidomide 4 mg orally once daily on days 1 to 21 of each 28-day cycle.
Number of Participants With Progression Free Survival (PFS) Events Participants with PFS events	2 Participants	0 Participants	1 Participants	1 Participants	0 Participants	0 Participants	4 Participants	1 Participants
Number of Participants With Progression Free Survival (PFS) Events Participants who were censored	3 Participants	3 Participants	5 Participants	2 Participants	3 Participants	7 Participants	6 Participants	7 Participants

SECONDARY outcome

Timeframe: Day 1 of cycle 1 up to the end of study visit (where each cycle was 28 days); median treatment duration in Part 1 was 11.43 weeks and in Part 2 was 28 weeks

Population: The efficacy analysis set included all participants, excluding roll-over participants, who were included in the safety analysis set, and had a baseline disease assessment and at least 1 post-baseline disease assessment.

PFS was defined as the number of months from a participant's first dose of study treatment to the earlier of disease progression or death due to any cause. Median PFS was estimated using the Kaplan-Meier method. 95% CIs were estimated using the method by Klein and Moeschberger (1997) with log-log transformation. PFS data was censored: participants alive and no documented disease progression at time of analysis were censored at date of last disease assessment; participants alive with no disease assessment were censored at the first study dose date; participants alive without documented disease progression, with withdrawn consent were censored at date of last disease assessment before consent withdrawal; and for participants who started anti-cancer therapy other than study treatment prior to documentation of disease progression were censored at date of last disease assessment prior to starting new therapy.

Outcome measures

Measure	Oprozomib GR 200 mg/Day + Pomalidomide + Dexamethasone n=5 Participants In Part 2, participants received oprozomib GR 150 mg/day on days 1 and 2 of cycle 1, and oprozomib GR 200 mg/day administered orally every week on 2 consecutive days from cycle 1 day 8 onwards (2/7 schedule), for up to 10 months. Participants also received dexamethasone 20 mg orally (days 1, 2, 8, 9, 15, 16, 22, and 23 of each 28-day cycle), and pomalidomide 4 mg orally once daily on days 1 to 21 of each 28-day cycle.	Oprozomib IR 150 mg/Day + Dexamethsone n=3 Participants In Part 1, participants received oprozomib IR 150 mg/day administered orally every week on 2 consecutive days (2/7 schedule) in combination with dexamethasone 20 mg orally (days 1, 2, 8, 9, 15, 16, 22, and 23 of each 28-day cycle), for up to 10 months.	Oprozomib GR 150 mg/Day + Dexamethasone n=6 Participants In Part 1, participants received oprozomib GR 150 mg/day administered orally every week on 2 consecutive days (2/7 schedule) in combination with dexamethasone 20 mg orally (days 1, 2, 8, 9, 15, 16, 22, and 23 of each 28-day cycle), for up to 10 months.	Oprozomib IR 150 mg/Day + Pomalidomide + Dexamethasone n=3 Participants In Part 2, participants received oprozomib IR 150 mg/day administered orally every week on 2 consecutive days (2/7 schedule) in combination with dexamethasone 20 mg orally (days 1, 2, 8, 9, 15, 16, 22, and 23 of each 28-day cycle), for up to 10 months. Participants also received pomalidomide 4 mg orally once daily on days 1 to 21 of each 28-day cycle.	Oprozomib GR 150 mg/Day + Pomalidomide + Dexamethasone n=3 Participants In Part 2, participants received oprozomib GR 150 mg/day administered orally every week on 2 consecutive days (2/7 schedule) in combination with dexamethasone 20 mg orally (days 1, 2, 8, 9, 15, 16, 22, and 23 of each 28-day cycle), for up to 10 months. Participants also received pomalidomide 4 mg orally once daily on days 1 to 21 of each 28-day cycle.	Oprozomib IR 200 mg/Day + Pomalidomide + Dexamethasone n=7 Participants In Part 2, participants received oprozomib IR 150 mg/day on days 1 and 2 of cycle 1, and oprozomib IR 200 mg/day administered orally every week on 2 consecutive days from cycle 1 day 8 onwards (2/7 schedule), for up to 10 months. Participants also received dexamethasone 20 mg orally (days 1, 2, 8, 9, 15, 16, 22, and 23 of each 28-day cycle), and pomalidomide 4 mg orally once daily on days 1 to 21 of each 28-day cycle.	Oprozomib IR 225 mg/Day + Pomalidomide + Dexamethasone n=10 Participants In Part 2, participants received oprozomib IR 150 mg/day on days 1 and 2 of cycle 1, and oprozomib IR 225 mg/day administered orally every week on 2 consecutive days from cycle 1 day 8 onwards (2/7 schedule), for up to 10 months. Participants also received dexamethasone 20 mg orally (days 1, 2, 8, 9, 15, 16, 22, and 23 of each 28-day cycle), and pomalidomide 4 mg orally once daily on days 1 to 21 of each 28-day cycle.	Oprozomib IR 250 mg/Day + Pomalidomide + Dexamethasone n=8 Participants In Part 2, participants received oprozomib IR 150 mg/day on days 1 and 2 of cycle 1, and oprozomib IR 250 mg/day administered orally every week on 2 consecutive days from cycle 1 day 8 onwards (2/7 schedule), for up to 10 months. Participants also received dexamethasone 20 mg orally (days 1, 2, 8, 9, 15, 16, 22, and 23 of each 28-day cycle), and pomalidomide 4 mg orally once daily on days 1 to 21 of each 28-day cycle.
Kaplan-Meier Estimate of PFS	NA months Interval 1.5 to The median and upper 95% CI could not be estimated due to too few events.	NA months The median and upper and lower 95% CIs could not be estimated due to too few events.	NA months Interval 2.7 to The median and upper 95% CI could not be estimated due to too few events.	14.24 months Due to the low numbers of participants (3) there are too few events (1) that impacted the estimate of survival function to no variation, hence the 95% CIs could not be estimated.	NA months The median and upper and lower 95% CIs could not be estimated due to too few events.	NA months The median and upper and lower 95% CIs could not be estimated due to too few events.	17.50 months Interval 5.6 to The upper 95% CI could not be estimated due to too few events.	NA months Interval 29.5 to The median and upper 95% CI could not be estimated due to too few events.

SECONDARY outcome

Timeframe: Day 1 of cycle 1 up to the end of study visit (where each cycle was 28 days); median treatment duration in Part 1 was 11.43 weeks and in Part 2 was 28 weeks

Population: The efficacy analysis set included all participants, excluding roll-over participants, who were included in the safety analysis set, and had a baseline disease assessment and at least 1 post-baseline disease assessment. Participants who did not achieve an objective response were excluded from the analysis of DOR. Participants who responded and had not progressed while on study were censored at the date of assessment of the last evaluable tumor assessment.

DOR, presented in months, was defined as the number of days between the date of the first tumor assessment indicating an objective response (PR or better) through to the subsequent date of progression or death due to any cause, or where applicable date of censoring (date of first progressive disease assessment or death or date of censoring - date of the first objective response result + 1/30.4). Median PFS was estimated using the Kaplan-Meier method. 95% confidence intervals were estimated using the method by Klein and Moeschberger (1997) with log-log transformation.

Outcome measures

Measure	Oprozomib GR 200 mg/Day + Pomalidomide + Dexamethasone n=3 Participants In Part 2, participants received oprozomib GR 150 mg/day on days 1 and 2 of cycle 1, and oprozomib GR 200 mg/day administered orally every week on 2 consecutive days from cycle 1 day 8 onwards (2/7 schedule), for up to 10 months. Participants also received dexamethasone 20 mg orally (days 1, 2, 8, 9, 15, 16, 22, and 23 of each 28-day cycle), and pomalidomide 4 mg orally once daily on days 1 to 21 of each 28-day cycle.	Oprozomib IR 150 mg/Day + Dexamethsone n=2 Participants In Part 1, participants received oprozomib IR 150 mg/day administered orally every week on 2 consecutive days (2/7 schedule) in combination with dexamethasone 20 mg orally (days 1, 2, 8, 9, 15, 16, 22, and 23 of each 28-day cycle), for up to 10 months.	Oprozomib GR 150 mg/Day + Dexamethasone n=1 Participants In Part 1, participants received oprozomib GR 150 mg/day administered orally every week on 2 consecutive days (2/7 schedule) in combination with dexamethasone 20 mg orally (days 1, 2, 8, 9, 15, 16, 22, and 23 of each 28-day cycle), for up to 10 months.	Oprozomib IR 150 mg/Day + Pomalidomide + Dexamethasone n=1 Participants In Part 2, participants received oprozomib IR 150 mg/day administered orally every week on 2 consecutive days (2/7 schedule) in combination with dexamethasone 20 mg orally (days 1, 2, 8, 9, 15, 16, 22, and 23 of each 28-day cycle), for up to 10 months. Participants also received pomalidomide 4 mg orally once daily on days 1 to 21 of each 28-day cycle.	Oprozomib GR 150 mg/Day + Pomalidomide + Dexamethasone In Part 2, participants received oprozomib GR 150 mg/day administered orally every week on 2 consecutive days (2/7 schedule) in combination with dexamethasone 20 mg orally (days 1, 2, 8, 9, 15, 16, 22, and 23 of each 28-day cycle), for up to 10 months. Participants also received pomalidomide 4 mg orally once daily on days 1 to 21 of each 28-day cycle.	Oprozomib IR 200 mg/Day + Pomalidomide + Dexamethasone n=6 Participants In Part 2, participants received oprozomib IR 150 mg/day on days 1 and 2 of cycle 1, and oprozomib IR 200 mg/day administered orally every week on 2 consecutive days from cycle 1 day 8 onwards (2/7 schedule), for up to 10 months. Participants also received dexamethasone 20 mg orally (days 1, 2, 8, 9, 15, 16, 22, and 23 of each 28-day cycle), and pomalidomide 4 mg orally once daily on days 1 to 21 of each 28-day cycle.	Oprozomib IR 225 mg/Day + Pomalidomide + Dexamethasone n=6 Participants In Part 2, participants received oprozomib IR 150 mg/day on days 1 and 2 of cycle 1, and oprozomib IR 225 mg/day administered orally every week on 2 consecutive days from cycle 1 day 8 onwards (2/7 schedule), for up to 10 months. Participants also received dexamethasone 20 mg orally (days 1, 2, 8, 9, 15, 16, 22, and 23 of each 28-day cycle), and pomalidomide 4 mg orally once daily on days 1 to 21 of each 28-day cycle.	Oprozomib IR 250 mg/Day + Pomalidomide + Dexamethasone n=7 Participants In Part 2, participants received oprozomib IR 150 mg/day on days 1 and 2 of cycle 1, and oprozomib IR 250 mg/day administered orally every week on 2 consecutive days from cycle 1 day 8 onwards (2/7 schedule), for up to 10 months. Participants also received dexamethasone 20 mg orally (days 1, 2, 8, 9, 15, 16, 22, and 23 of each 28-day cycle), and pomalidomide 4 mg orally once daily on days 1 to 21 of each 28-day cycle.
Kaplan-Meier Estimate of Duration of Response (DOR)	NA months The median, upper and lower 95% CIs could not be estimated due to too few events.	NA months The median, upper and lower 95% CIs could not be estimated due to too few events.	NA months The median, upper and lower 95% CIs could not be estimated due to too few events.	NA months The median, upper and lower 95% CIs could not be estimated due to too few events.	—	NA months The median, upper and lower 95% CIs could not be estimated due to too few events.	16.6 months Interval 3.7 to The upper 95% CI could not be estimated due to too few events.	NA months Interval 28.6 to The median could not be estimated due to too few events. The lower bound 95% CI was estimated from observed data that were available (25% percentile).

Adverse Events

Oprozomib IR 150 mg/Day + Dexamethsone

Serious events: 2 serious events

Other events: 4 other events

Deaths: 0 deaths

Oprozomib GR 150 mg/Day + Dexamethasone

Serious events: 2 serious events

Other events: 8 other events

Deaths: 0 deaths

Oprozomib IR 150 mg/Day + Pomalidomide + Dexamethasone

Serious events: 2 serious events

Other events: 4 other events

Deaths: 1 deaths

Oprozomib GR 150 mg/Day + Pomalidomide + Dexamethasone

Serious events: 4 serious events

Other events: 4 other events

Deaths: 0 deaths

Oprozomib IR 200 mg/Day + Pomalidomide + Dexamethasone

Serious events: 6 serious events

Other events: 8 other events

Deaths: 0 deaths

Oprozomib GR 200 mg/Day + Pomalidomide + Dexamethasone

Serious events: 5 serious events

Other events: 5 other events

Deaths: 2 deaths

Oprozomib IR 225 mg/Day + Pomalidomide + Dexamethasone

Serious events: 3 serious events

Other events: 10 other events

Deaths: 1 deaths

Oprozomib IR 250 mg/Day + Pomalidomide + Dexamethasone

Serious events: 4 serious events

Other events: 8 other events

Deaths: 0 deaths

Open-label Roll-over

Serious events: 4 serious events

Other events: 7 other events

Deaths: 0 deaths

Serious adverse events

Measure	Oprozomib IR 150 mg/Day + Dexamethsone n=5 participants at risk In Part 1, participants received oprozomib IR 150 mg/day administered orally every week on 2 consecutive days (2/7 schedule) in combination with dexamethasone 20 mg orally (days 1, 2, 8, 9, 15, 16, 22, and 23 of each 28-day cycle), for up to 10 months.	Oprozomib GR 150 mg/Day + Dexamethasone n=8 participants at risk In Part 1, participants received oprozomib GR 150 mg/day administered orally every week on 2 consecutive days (2/7 schedule) in combination with dexamethasone 20 mg orally (days 1, 2, 8, 9, 15, 16, 22, and 23 of each 28-day cycle), for up to 10 months.	Oprozomib IR 150 mg/Day + Pomalidomide + Dexamethasone n=4 participants at risk In Part 2, participants received oprozomib IR 150 mg/day administered orally every week on 2 consecutive days (2/7 schedule) in combination with dexamethasone 20 mg orally (days 1, 2, 8, 9, 15, 16, 22, and 23 of each 28-day cycle), for up to 10 months. Participants also received pomalidomide 4 mg orally once daily on days 1 to 21 of each 28-day cycle.	Oprozomib GR 150 mg/Day + Pomalidomide + Dexamethasone n=4 participants at risk In Part 2, participants received oprozomib GR 150 mg/day administered orally every week on 2 consecutive days (2/7 schedule) in combination with dexamethasone 20 mg orally (days 1, 2, 8, 9, 15, 16, 22, and 23 of each 28-day cycle), for up to 10 months. Participants also received pomalidomide 4 mg orally once daily on days 1 to 21 of each 28-day cycle.	Oprozomib IR 200 mg/Day + Pomalidomide + Dexamethasone n=8 participants at risk In Part 2, participants received oprozomib IR 150 mg/day on days 1 and 2 of cycle 1, and oprozomib IR 200 mg/day administered orally every week on 2 consecutive days from cycle 1 day 8 onwards (2/7 schedule), for up to 10 months. Participants also received dexamethasone 20 mg orally (days 1, 2, 8, 9, 15, 16, 22, and 23 of each 28-day cycle), and pomalidomide 4 mg orally once daily on days 1 to 21 of each 28-day cycle.	Oprozomib GR 200 mg/Day + Pomalidomide + Dexamethasone n=5 participants at risk In Part 2, participants received oprozomib GR 150 mg/day on days 1 and 2 of cycle 1, and oprozomib GR 200 mg/day administered orally every week on 2 consecutive days from cycle 1 day 8 onwards (2/7 schedule), for up to 10 months. Participants also received dexamethasone 20 mg orally (days 1, 2, 8, 9, 15, 16, 22, and 23 of each 28-day cycle), and pomalidomide 4 mg orally once daily on days 1 to 21 of each 28-day cycle.	Oprozomib IR 225 mg/Day + Pomalidomide + Dexamethasone n=10 participants at risk In Part 2, participants received oprozomib IR 150 mg/day on days 1 and 2 of cycle 1, and oprozomib IR 225 mg/day administered orally every week on 2 consecutive days from cycle 1 day 8 onwards (2/7 schedule), for up to 10 months. Participants also received dexamethasone 20 mg orally (days 1, 2, 8, 9, 15, 16, 22, and 23 of each 28-day cycle), and pomalidomide 4 mg orally once daily on days 1 to 21 of each 28-day cycle.	Oprozomib IR 250 mg/Day + Pomalidomide + Dexamethasone n=8 participants at risk In Part 2, participants received oprozomib IR 150 mg/day on days 1 and 2 of cycle 1, and oprozomib IR 250 mg/day administered orally every week on 2 consecutive days from cycle 1 day 8 onwards (2/7 schedule), for up to 10 months. Participants also received dexamethasone 20 mg orally (days 1, 2, 8, 9, 15, 16, 22, and 23 of each 28-day cycle), and pomalidomide 4 mg orally once daily on days 1 to 21 of each 28-day cycle	Open-label Roll-over n=7 participants at risk Eligible participants who had enrolled on separate Amgen oprozomib studies (2011-001 \[NCT01416428\], 2012-001 \[NCT01832727\], OPZ003 \[NCT01881789\], OPZ007 \[NCT01999335\], and OPZ009 \[NCT02244112\]) and were receiving oprozomib as monotherapy, or a combination of oprozomib with dexamethasone, continued treatment in research centers within the United States only. Participants continued receiving the previous dose/schedule of oprozomib GR formulation until disease progression, death, or unacceptable toxicity.
Blood and lymphatic system disorders Neutropenia	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	10.0% 1/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Blood and lymphatic system disorders Splenic infarction	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	25.0% 1/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Cardiac disorders Atrial fibrillation	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Cardiac disorders Ventricular tachycardia	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Ear and labyrinth disorders Eustachian tube dysfunction	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	20.0% 1/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Gastrointestinal disorders Constipation	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Gastrointestinal disorders Diarrhoea	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	25.0% 2/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Gastrointestinal disorders Gastritis	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	25.0% 1/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Gastrointestinal disorders Gastrointestinal haemorrhage	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	20.0% 1/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Gastrointestinal disorders Pancreatitis acute	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	14.3% 1/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Gastrointestinal disorders Small intestinal obstruction	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	25.0% 1/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Gastrointestinal disorders Vomiting	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
General disorders Non-cardiac chest pain	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	14.3% 1/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
General disorders Pyrexia	20.0% 1/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Infections and infestations Appendicitis	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Infections and infestations Bronchitis	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	25.0% 1/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	20.0% 2/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Infections and infestations COVID-19 pneumonia	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	10.0% 1/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Infections and infestations Cellulitis	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Infections and infestations Clostridium difficile infection	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Infections and infestations Diverticulitis	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	25.0% 2/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Infections and infestations Gastroenteritis norovirus	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Infections and infestations Gastroenteritis rotavirus	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Infections and infestations Infection	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	10.0% 1/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Infections and infestations Lower respiratory tract infection	20.0% 1/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	25.0% 1/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Infections and infestations Parainfluenzae virus infection	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	10.0% 1/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Infections and infestations Pasteurella infection	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Infections and infestations Pneumonia	20.0% 1/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	25.0% 1/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	75.0% 3/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	40.0% 2/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	10.0% 1/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	25.0% 2/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	14.3% 1/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Infections and infestations Pneumonia aspiration	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Infections and infestations Pneumonia haemophilus	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	10.0% 1/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Infections and infestations Pneumonia parainfluenzae viral	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Infections and infestations Pneumonia respiratory syncytial viral	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	25.0% 1/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Infections and infestations Respiratory syncytial virus infection	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Infections and infestations Respiratory tract infection	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	10.0% 1/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Infections and infestations Sepsis	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Metabolism and nutrition disorders Hyperglycaemia	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	20.0% 1/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Musculoskeletal and connective tissue disorders Osteonecrosis of jaw	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	10.0% 1/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Musculoskeletal and connective tissue disorders Pathological fracture	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	25.0% 1/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Acute myeloid leukaemia	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	14.3% 1/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Squamous cell carcinoma	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	14.3% 1/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Nervous system disorders Cerebrovascular accident	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	25.0% 1/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	20.0% 1/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Nervous system disorders Posterior reversible encephalopathy syndrome	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	25.0% 1/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Nervous system disorders Stroke in evolution	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Nervous system disorders Syncope	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Renal and urinary disorders Acute kidney injury	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	20.0% 1/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Respiratory, thoracic and mediastinal disorders Chronic obstructive pulmonary disease	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	10.0% 1/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Respiratory, thoracic and mediastinal disorders Dyspnoea	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	20.0% 1/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Respiratory, thoracic and mediastinal disorders Pulmonary embolism	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Skin and subcutaneous tissue disorders Erythema multiforme	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	20.0% 1/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.

Other adverse events

Measure	Oprozomib IR 150 mg/Day + Dexamethsone n=5 participants at risk In Part 1, participants received oprozomib IR 150 mg/day administered orally every week on 2 consecutive days (2/7 schedule) in combination with dexamethasone 20 mg orally (days 1, 2, 8, 9, 15, 16, 22, and 23 of each 28-day cycle), for up to 10 months.	Oprozomib GR 150 mg/Day + Dexamethasone n=8 participants at risk In Part 1, participants received oprozomib GR 150 mg/day administered orally every week on 2 consecutive days (2/7 schedule) in combination with dexamethasone 20 mg orally (days 1, 2, 8, 9, 15, 16, 22, and 23 of each 28-day cycle), for up to 10 months.	Oprozomib IR 150 mg/Day + Pomalidomide + Dexamethasone n=4 participants at risk In Part 2, participants received oprozomib IR 150 mg/day administered orally every week on 2 consecutive days (2/7 schedule) in combination with dexamethasone 20 mg orally (days 1, 2, 8, 9, 15, 16, 22, and 23 of each 28-day cycle), for up to 10 months. Participants also received pomalidomide 4 mg orally once daily on days 1 to 21 of each 28-day cycle.	Oprozomib GR 150 mg/Day + Pomalidomide + Dexamethasone n=4 participants at risk In Part 2, participants received oprozomib GR 150 mg/day administered orally every week on 2 consecutive days (2/7 schedule) in combination with dexamethasone 20 mg orally (days 1, 2, 8, 9, 15, 16, 22, and 23 of each 28-day cycle), for up to 10 months. Participants also received pomalidomide 4 mg orally once daily on days 1 to 21 of each 28-day cycle.	Oprozomib IR 200 mg/Day + Pomalidomide + Dexamethasone n=8 participants at risk In Part 2, participants received oprozomib IR 150 mg/day on days 1 and 2 of cycle 1, and oprozomib IR 200 mg/day administered orally every week on 2 consecutive days from cycle 1 day 8 onwards (2/7 schedule), for up to 10 months. Participants also received dexamethasone 20 mg orally (days 1, 2, 8, 9, 15, 16, 22, and 23 of each 28-day cycle), and pomalidomide 4 mg orally once daily on days 1 to 21 of each 28-day cycle.	Oprozomib GR 200 mg/Day + Pomalidomide + Dexamethasone n=5 participants at risk In Part 2, participants received oprozomib GR 150 mg/day on days 1 and 2 of cycle 1, and oprozomib GR 200 mg/day administered orally every week on 2 consecutive days from cycle 1 day 8 onwards (2/7 schedule), for up to 10 months. Participants also received dexamethasone 20 mg orally (days 1, 2, 8, 9, 15, 16, 22, and 23 of each 28-day cycle), and pomalidomide 4 mg orally once daily on days 1 to 21 of each 28-day cycle.	Oprozomib IR 225 mg/Day + Pomalidomide + Dexamethasone n=10 participants at risk In Part 2, participants received oprozomib IR 150 mg/day on days 1 and 2 of cycle 1, and oprozomib IR 225 mg/day administered orally every week on 2 consecutive days from cycle 1 day 8 onwards (2/7 schedule), for up to 10 months. Participants also received dexamethasone 20 mg orally (days 1, 2, 8, 9, 15, 16, 22, and 23 of each 28-day cycle), and pomalidomide 4 mg orally once daily on days 1 to 21 of each 28-day cycle.	Oprozomib IR 250 mg/Day + Pomalidomide + Dexamethasone n=8 participants at risk In Part 2, participants received oprozomib IR 150 mg/day on days 1 and 2 of cycle 1, and oprozomib IR 250 mg/day administered orally every week on 2 consecutive days from cycle 1 day 8 onwards (2/7 schedule), for up to 10 months. Participants also received dexamethasone 20 mg orally (days 1, 2, 8, 9, 15, 16, 22, and 23 of each 28-day cycle), and pomalidomide 4 mg orally once daily on days 1 to 21 of each 28-day cycle	Open-label Roll-over n=7 participants at risk Eligible participants who had enrolled on separate Amgen oprozomib studies (2011-001 \[NCT01416428\], 2012-001 \[NCT01832727\], OPZ003 \[NCT01881789\], OPZ007 \[NCT01999335\], and OPZ009 \[NCT02244112\]) and were receiving oprozomib as monotherapy, or a combination of oprozomib with dexamethasone, continued treatment in research centers within the United States only. Participants continued receiving the previous dose/schedule of oprozomib GR formulation until disease progression, death, or unacceptable toxicity.
Blood and lymphatic system disorders Thrombocytopenia	20.0% 1/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	20.0% 1/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	20.0% 2/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Cardiac disorders Atrial fibrillation	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	25.0% 1/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Cardiac disorders Palpitations	20.0% 1/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	14.3% 1/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Cardiac disorders Sinus bradycardia	20.0% 1/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Cardiac disorders Sinus tachycardia	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Cardiac disorders Tachycardia	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	10.0% 1/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Ear and labyrinth disorders Cerumen impaction	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	14.3% 1/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Ear and labyrinth disorders Ear congestion	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	10.0% 1/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Ear and labyrinth disorders Ear discomfort	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	14.3% 1/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Ear and labyrinth disorders Ear pruritus	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	10.0% 1/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Ear and labyrinth disorders Eustachian tube dysfunction	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	20.0% 1/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Ear and labyrinth disorders External ear inflammation	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Ear and labyrinth disorders Tinnitus	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Endocrine disorders Cushingoid	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Endocrine disorders Steroid withdrawal syndrome	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Eye disorders Blepharitis	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Eye disorders Cataract	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	25.0% 1/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	10.0% 1/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Eye disorders Cataract nuclear	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Eye disorders Conjunctival disorder	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Eye disorders Diplopia	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Eye disorders Dry eye	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	20.0% 1/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Eye disorders Eye discharge	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Eye disorders Eye disorder	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	10.0% 1/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Eye disorders Eye pain	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Eye disorders Eye pruritus	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	14.3% 1/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Eye disorders Lacrimation increased	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	25.0% 1/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Eye disorders Retinal artery occlusion	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Eye disorders Vision blurred	20.0% 1/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	25.0% 2/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	10.0% 1/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	14.3% 1/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Gastrointestinal disorders Abdominal discomfort	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	25.0% 1/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	20.0% 1/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Gastrointestinal disorders Abdominal distension	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	37.5% 3/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	20.0% 1/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	20.0% 2/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Gastrointestinal disorders Abdominal mass	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	25.0% 1/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Gastrointestinal disorders Abdominal pain	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	25.0% 1/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	20.0% 1/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	30.0% 3/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	25.0% 2/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	28.6% 2/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Gastrointestinal disorders Abdominal pain upper	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	10.0% 1/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Gastrointestinal disorders Anal incontinence	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Gastrointestinal disorders Constipation	80.0% 4/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	37.5% 3/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	50.0% 2/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	25.0% 1/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	50.0% 4/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	60.0% 3/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	30.0% 3/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	75.0% 6/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	14.3% 1/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Gastrointestinal disorders Dental caries	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	10.0% 1/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Gastrointestinal disorders Diarrhoea	40.0% 2/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	62.5% 5/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	75.0% 3/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	50.0% 2/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	62.5% 5/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	80.0% 4/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	80.0% 8/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	100.0% 8/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	28.6% 2/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Gastrointestinal disorders Dry mouth	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	10.0% 1/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	25.0% 2/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Gastrointestinal disorders Duodenal ulcer	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	25.0% 1/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Gastrointestinal disorders Dyspepsia	20.0% 1/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	10.0% 1/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Gastrointestinal disorders Dysphagia	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Gastrointestinal disorders Eructation	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Gastrointestinal disorders Flatulence	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	20.0% 1/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	37.5% 3/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Gastrointestinal disorders Gastrointestinal pain	20.0% 1/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Gastrointestinal disorders Gastrooesophageal reflux disease	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	25.0% 2/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	20.0% 2/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	25.0% 2/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Gastrointestinal disorders Haematochezia	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	14.3% 1/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Gastrointestinal disorders Haemorrhoidal haemorrhage	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Gastrointestinal disorders Haemorrhoids	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Gastrointestinal disorders Hiatus hernia	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Gastrointestinal disorders Nausea	80.0% 4/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	87.5% 7/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	75.0% 3/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	75.0% 3/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	75.0% 6/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	60.0% 3/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	80.0% 8/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	100.0% 8/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	28.6% 2/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Gastrointestinal disorders Rectal haemorrhage	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	10.0% 1/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Gastrointestinal disorders Salivary hypersecretion	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Gastrointestinal disorders Stomatitis	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	10.0% 1/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Gastrointestinal disorders Vomiting	60.0% 3/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	37.5% 3/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	50.0% 2/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	25.0% 1/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	75.0% 6/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	60.0% 3/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	70.0% 7/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	87.5% 7/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	14.3% 1/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
General disorders Asthenia	20.0% 1/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	25.0% 1/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	10.0% 1/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
General disorders Catheter site bruise	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
General disorders Chest discomfort	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
General disorders Chest pain	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	28.6% 2/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
General disorders Chills	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	25.0% 1/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
General disorders Face oedema	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	20.0% 1/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
General disorders Fatigue	60.0% 3/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	50.0% 4/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	50.0% 2/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	75.0% 3/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	37.5% 3/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	40.0% 2/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	60.0% 6/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	62.5% 5/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
General disorders Feeling jittery	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	20.0% 1/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
General disorders Influenza like illness	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	50.0% 4/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	20.0% 1/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	10.0% 1/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	25.0% 2/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
General disorders Injection site bruising	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
General disorders Localised oedema	20.0% 1/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
General disorders Malaise	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
General disorders Mucosal inflammation	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	14.3% 1/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
General disorders Non-cardiac chest pain	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	14.3% 1/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
General disorders Oedema	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	25.0% 1/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
General disorders Oedema peripheral	20.0% 1/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	25.0% 1/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	25.0% 1/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	37.5% 3/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	60.0% 3/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	50.0% 5/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
General disorders Pain	20.0% 1/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
General disorders Peripheral swelling	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	20.0% 2/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	25.0% 2/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
General disorders Puncture site bruise	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	20.0% 1/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
General disorders Pyrexia	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	50.0% 2/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	25.0% 2/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	20.0% 1/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	20.0% 2/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	37.5% 3/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	14.3% 1/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
General disorders Secretion discharge	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	20.0% 1/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
General disorders Swelling	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	14.3% 1/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
General disorders Temperature regulation disorder	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	10.0% 1/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
General disorders Vessel puncture site bruise	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Hepatobiliary disorders Hyperbilirubinaemia	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Immune system disorders Immunisation reaction	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Immune system disorders Seasonal allergy	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Infections and infestations Bronchitis	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	10.0% 1/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	14.3% 1/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Infections and infestations Bronchitis viral	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Infections and infestations COVID-19	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	14.3% 1/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Infections and infestations COVID-19 pneumonia	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	14.3% 1/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Infections and infestations Campylobacter infection	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	14.3% 1/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Infections and infestations Candida infection	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	10.0% 1/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Infections and infestations Cellulitis	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	20.0% 2/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Infections and infestations Coronavirus infection	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	10.0% 1/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Infections and infestations Diverticulitis	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Infections and infestations Ear infection	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Infections and infestations Eye infection	20.0% 1/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Infections and infestations Folliculitis	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	14.3% 1/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Infections and infestations Gingivitis	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	14.3% 1/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Infections and infestations Herpes zoster	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	10.0% 1/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Infections and infestations Influenza	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	10.0% 1/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Infections and infestations Lower respiratory tract infection	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	25.0% 1/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	20.0% 1/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	37.5% 3/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Infections and infestations Metapneumovirus infection	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	25.0% 1/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Infections and infestations Moraxella infection	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	10.0% 1/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Infections and infestations Mucosal infection	20.0% 1/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Infections and infestations Nasopharyngitis	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	25.0% 1/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	20.0% 1/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Infections and infestations Oesophageal candidiasis	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	25.0% 1/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Infections and infestations Oropharyngeal candidiasis	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Infections and infestations Parainfluenzae virus infection	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	10.0% 1/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Infections and infestations Paronychia	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	10.0% 1/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Infections and infestations Pneumonia	40.0% 2/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	20.0% 1/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	10.0% 1/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Infections and infestations Pneumonia aspiration	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	20.0% 1/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Infections and infestations Respiratory syncytial virus infection	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Infections and infestations Respiratory tract infection	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	25.0% 1/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	10.0% 1/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Infections and infestations Sepsis	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	20.0% 1/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Infections and infestations Sinusitis	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	20.0% 1/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	10.0% 1/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	28.6% 2/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Infections and infestations Soft tissue infection	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	14.3% 1/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Infections and infestations Staphylococcal infection	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Infections and infestations Upper respiratory tract infection	40.0% 2/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	25.0% 2/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	25.0% 1/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	37.5% 3/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	40.0% 2/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	10.0% 1/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	62.5% 5/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Infections and infestations Urinary tract infection	20.0% 1/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	25.0% 1/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	25.0% 1/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	20.0% 1/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Infections and infestations Urinary tract infection bacterial	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	10.0% 1/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Infections and infestations Wound infection	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Injury, poisoning and procedural complications Accidental overdose	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	10.0% 1/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Injury, poisoning and procedural complications Clavicle fracture	20.0% 1/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Injury, poisoning and procedural complications Contusion	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	25.0% 2/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Injury, poisoning and procedural complications Fall	20.0% 1/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	25.0% 1/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	37.5% 3/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	20.0% 2/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	37.5% 3/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	14.3% 1/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Injury, poisoning and procedural complications Fracture	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	10.0% 1/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Injury, poisoning and procedural complications Head injury	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Injury, poisoning and procedural complications Heat exhaustion	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Injury, poisoning and procedural complications Infusion related reaction	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Injury, poisoning and procedural complications Limb injury	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	25.0% 1/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Injury, poisoning and procedural complications Overdose	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	20.0% 1/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Injury, poisoning and procedural complications Radiation injury	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Injury, poisoning and procedural complications Rib fracture	20.0% 1/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Injury, poisoning and procedural complications Skin abrasion	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	20.0% 1/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Injury, poisoning and procedural complications Sunburn	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Injury, poisoning and procedural complications Tendon rupture	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Injury, poisoning and procedural complications Tooth fracture	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Injury, poisoning and procedural complications Wound	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Injury, poisoning and procedural complications Wound complication	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Investigations Alanine aminotransferase increased	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	50.0% 2/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	14.3% 1/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Investigations Amylase increased	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	25.0% 2/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	14.3% 1/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Investigations Aspartate aminotransferase increased	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	25.0% 1/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	14.3% 1/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Investigations Blood alkaline phosphatase increased	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Investigations Blood bicarbonate decreased	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Investigations Blood cholesterol increased	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Investigations Blood creatine increased	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Investigations Blood creatinine increased	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Investigations Blood urine present	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Investigations Crystal urine present	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	20.0% 1/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Investigations Gamma-glutamyltransferase increased	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Investigations International normalised ratio increased	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Investigations Lipase increased	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	25.0% 1/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	25.0% 2/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	10.0% 1/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	37.5% 3/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	14.3% 1/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Investigations Lymphocyte count decreased	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	50.0% 2/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Investigations Neutrophil count decreased	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	25.0% 1/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	50.0% 2/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	25.0% 2/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	14.3% 1/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Investigations Neutrophil count increased	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Investigations Norovirus test positive	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Investigations Platelet count decreased	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	25.0% 1/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	25.0% 1/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	20.0% 1/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	10.0% 1/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Investigations Troponin I increased	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	25.0% 1/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Investigations Weight decreased	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	25.0% 1/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	10.0% 1/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	14.3% 1/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Investigations Weight increased	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	10.0% 1/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Investigations White blood cell count decreased	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	50.0% 2/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Metabolism and nutrition disorders Decreased appetite	40.0% 2/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	25.0% 1/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	25.0% 2/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	20.0% 1/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	10.0% 1/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Metabolism and nutrition disorders Dehydration	40.0% 2/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Metabolism and nutrition disorders Hypercalcaemia	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	20.0% 1/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	10.0% 1/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Metabolism and nutrition disorders Hyperglycaemia	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	25.0% 1/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	25.0% 1/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	25.0% 2/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	40.0% 2/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	14.3% 1/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Metabolism and nutrition disorders Hyperkalaemia	20.0% 1/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Metabolism and nutrition disorders Hyperuricaemia	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Metabolism and nutrition disorders Hypervolaemia	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	25.0% 1/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Metabolism and nutrition disorders Hypoalbuminaemia	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	25.0% 1/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Metabolism and nutrition disorders Hypocalcaemia	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	25.0% 1/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Metabolism and nutrition disorders Hypokalaemia	20.0% 1/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	25.0% 1/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	25.0% 1/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	37.5% 3/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	60.0% 3/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	37.5% 3/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Metabolism and nutrition disorders Hypomagnesaemia	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	25.0% 1/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	60.0% 3/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Metabolism and nutrition disorders Hyponatraemia	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	20.0% 1/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	10.0% 1/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Metabolism and nutrition disorders Hypophosphataemia	40.0% 2/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	25.0% 1/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	25.0% 2/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	20.0% 1/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	10.0% 1/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Metabolism and nutrition disorders Tumour lysis syndrome	20.0% 1/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Metabolism and nutrition disorders Type 2 diabetes mellitus	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Musculoskeletal and connective tissue disorders Arthralgia	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	37.5% 3/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	20.0% 1/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	10.0% 1/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Musculoskeletal and connective tissue disorders Arthritis	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Musculoskeletal and connective tissue disorders Back pain	20.0% 1/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	50.0% 2/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	37.5% 3/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	60.0% 3/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	20.0% 2/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Musculoskeletal and connective tissue disorders Bone pain	20.0% 1/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	25.0% 2/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Musculoskeletal and connective tissue disorders Flank pain	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Musculoskeletal and connective tissue disorders Haemarthrosis	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Musculoskeletal and connective tissue disorders Limb discomfort	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Musculoskeletal and connective tissue disorders Limb mass	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Musculoskeletal and connective tissue disorders Muscle spasms	20.0% 1/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	25.0% 2/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	10.0% 1/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	25.0% 2/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Musculoskeletal and connective tissue disorders Muscle tightness	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Musculoskeletal and connective tissue disorders Muscular weakness	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	25.0% 1/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	10.0% 1/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Musculoskeletal and connective tissue disorders Musculoskeletal chest pain	20.0% 1/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	25.0% 2/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	20.0% 1/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	20.0% 2/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Musculoskeletal and connective tissue disorders Musculoskeletal pain	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Musculoskeletal and connective tissue disorders Musculoskeletal stiffness	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Musculoskeletal and connective tissue disorders Myalgia	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	20.0% 1/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	10.0% 1/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Musculoskeletal and connective tissue disorders Neck pain	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	20.0% 1/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	25.0% 2/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Musculoskeletal and connective tissue disorders Osteoarthritis	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Musculoskeletal and connective tissue disorders Osteonecrosis	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	14.3% 1/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Musculoskeletal and connective tissue disorders Osteonecrosis of jaw	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	10.0% 1/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Musculoskeletal and connective tissue disorders Osteoporosis	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Musculoskeletal and connective tissue disorders Pain in extremity	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	25.0% 1/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	20.0% 1/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	30.0% 3/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Musculoskeletal and connective tissue disorders Tendonitis	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Basal cell carcinoma	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	14.3% 1/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Bladder neoplasm	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	14.3% 1/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Blood and lymphatic system disorders Anaemia	20.0% 1/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	25.0% 2/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	75.0% 3/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	25.0% 1/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	25.0% 2/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	40.0% 2/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	30.0% 3/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	28.6% 2/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Blood and lymphatic system disorders Febrile neutropenia	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	25.0% 1/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Blood and lymphatic system disorders Haemolysis	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	25.0% 1/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Blood and lymphatic system disorders Iron deficiency anaemia	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	10.0% 1/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Blood and lymphatic system disorders Leukopenia	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	10.0% 1/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Blood and lymphatic system disorders Neutropenia	20.0% 1/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	50.0% 2/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	25.0% 2/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	20.0% 1/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	30.0% 3/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	14.3% 1/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Renal and urinary disorders Incontinence	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	20.0% 1/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Renal and urinary disorders Micturition urgency	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	14.3% 1/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Renal and urinary disorders Myeloma cast nephropathy	20.0% 1/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Renal and urinary disorders Nocturia	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	10.0% 1/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Renal and urinary disorders Pollakiuria	20.0% 1/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Renal and urinary disorders Proteinuria	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Renal and urinary disorders Urinary hesitation	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Renal and urinary disorders Urinary incontinence	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	10.0% 1/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	25.0% 2/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Renal and urinary disorders Urinary retention	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Respiratory, thoracic and mediastinal disorders Chronic obstructive pulmonary disease	20.0% 1/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Respiratory, thoracic and mediastinal disorders Cough	40.0% 2/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	25.0% 1/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	50.0% 2/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	25.0% 2/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	40.0% 2/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	50.0% 5/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	14.3% 1/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Respiratory, thoracic and mediastinal disorders Dysphonia	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	25.0% 1/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Respiratory, thoracic and mediastinal disorders Dyspnoea	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	37.5% 3/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	25.0% 1/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	25.0% 1/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	25.0% 2/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	40.0% 2/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	40.0% 4/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	37.5% 3/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	14.3% 1/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Respiratory, thoracic and mediastinal disorders Dyspnoea exertional	20.0% 1/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Respiratory, thoracic and mediastinal disorders Epistaxis	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	25.0% 1/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	10.0% 1/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Respiratory, thoracic and mediastinal disorders Hiccups	20.0% 1/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	25.0% 1/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	20.0% 2/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	37.5% 3/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Respiratory, thoracic and mediastinal disorders Hypoxia	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Respiratory, thoracic and mediastinal disorders Laryngeal inflammation	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Respiratory, thoracic and mediastinal disorders Nasal congestion	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	25.0% 1/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	20.0% 1/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	30.0% 3/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	14.3% 1/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Respiratory, thoracic and mediastinal disorders Obstructive sleep apnoea syndrome	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	10.0% 1/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Respiratory, thoracic and mediastinal disorders Oropharyngeal pain	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	40.0% 2/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	20.0% 2/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	25.0% 2/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	14.3% 1/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Respiratory, thoracic and mediastinal disorders Paranasal sinus discomfort	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	10.0% 1/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Respiratory, thoracic and mediastinal disorders Pharyngeal erythema	20.0% 1/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Respiratory, thoracic and mediastinal disorders Pneumonitis	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Respiratory, thoracic and mediastinal disorders Productive cough	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	20.0% 1/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	30.0% 3/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	14.3% 1/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Respiratory, thoracic and mediastinal disorders Pulmonary mass	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	20.0% 1/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Respiratory, thoracic and mediastinal disorders Pulmonary oedema	20.0% 1/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Respiratory, thoracic and mediastinal disorders Rhinitis allergic	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Respiratory, thoracic and mediastinal disorders Rhinorrhoea	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	20.0% 2/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Respiratory, thoracic and mediastinal disorders Upper-airway cough syndrome	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Respiratory, thoracic and mediastinal disorders Wheezing	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Skin and subcutaneous tissue disorders Actinic keratosis	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	14.3% 1/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Skin and subcutaneous tissue disorders Alopecia	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Skin and subcutaneous tissue disorders Cold sweat	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	10.0% 1/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Skin and subcutaneous tissue disorders Dermatitis	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	14.3% 1/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Skin and subcutaneous tissue disorders Dermatitis bullous	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Skin and subcutaneous tissue disorders Dry skin	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Skin and subcutaneous tissue disorders Erythema multiforme	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	20.0% 1/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Skin and subcutaneous tissue disorders Hyperhidrosis	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	25.0% 1/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	10.0% 1/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Skin and subcutaneous tissue disorders Night sweats	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	25.0% 2/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Skin and subcutaneous tissue disorders Pruritus	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	20.0% 1/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	10.0% 1/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Skin and subcutaneous tissue disorders Rash	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	25.0% 1/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	10.0% 1/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	25.0% 2/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Skin and subcutaneous tissue disorders Rash erythematous	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Skin and subcutaneous tissue disorders Rash maculo-papular	20.0% 1/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	10.0% 1/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Skin and subcutaneous tissue disorders Skin atrophy	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Skin and subcutaneous tissue disorders Skin induration	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Skin and subcutaneous tissue disorders Skin lesion	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Skin and subcutaneous tissue disorders Solar lentigo	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Surgical and medical procedures Skin lesion removal	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Vascular disorders Deep vein thrombosis	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	25.0% 1/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	20.0% 1/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Vascular disorders Flushing	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	25.0% 1/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	10.0% 1/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	25.0% 2/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Vascular disorders Haemorrhage	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	25.0% 1/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Vascular disorders Hot flush	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Vascular disorders Hypertension	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	20.0% 2/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	25.0% 2/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	14.3% 1/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Vascular disorders Hypotension	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	10.0% 1/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Vascular disorders Orthostatic hypotension	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Vascular disorders Phlebitis	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Vascular disorders Thrombophlebitis	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	20.0% 1/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Haemangioma of skin	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Keratoacanthoma	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Lipoma	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	20.0% 1/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Seborrhoeic keratosis	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Skin papilloma	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Squamous cell carcinoma	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Squamous cell carcinoma of skin	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Nervous system disorders Aphasia	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	14.3% 1/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Nervous system disorders Balance disorder	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Nervous system disorders Central nervous system lesion	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	25.0% 1/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Nervous system disorders Cerebral haematoma	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Nervous system disorders Cerebrovascular accident	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Nervous system disorders Depressed level of consciousness	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	10.0% 1/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Nervous system disorders Disturbance in attention	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Nervous system disorders Dizziness	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	25.0% 1/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	25.0% 2/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	20.0% 1/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	20.0% 2/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	25.0% 2/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Nervous system disorders Dysgeusia	20.0% 1/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	10.0% 1/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	25.0% 2/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Nervous system disorders Headache	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	37.5% 3/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	40.0% 2/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	20.0% 2/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	50.0% 4/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	14.3% 1/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Nervous system disorders Hyperaesthesia	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	20.0% 1/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Nervous system disorders Hypoaesthesia	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	25.0% 1/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	40.0% 2/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	10.0% 1/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Nervous system disorders Intention tremor	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Nervous system disorders Muscle spasticity	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Nervous system disorders Neuropathy peripheral	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	25.0% 2/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	25.0% 1/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Nervous system disorders Paraesthesia	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Nervous system disorders Peripheral sensory neuropathy	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	25.0% 1/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Nervous system disorders Presyncope	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	25.0% 2/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Nervous system disorders Somnolence	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Nervous system disorders Syncope	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Nervous system disorders Tremor	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	20.0% 2/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Psychiatric disorders Agitation	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	20.0% 1/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Psychiatric disorders Anxiety	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	25.0% 1/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Psychiatric disorders Depression	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	10.0% 1/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Psychiatric disorders Euphoric mood	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	20.0% 1/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Psychiatric disorders Insomnia	40.0% 2/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	25.0% 1/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	25.0% 2/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	20.0% 1/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	60.0% 6/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	37.5% 3/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Psychiatric disorders Irritability	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	20.0% 1/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Psychiatric disorders Mental status changes	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	25.0% 1/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Psychiatric disorders Mood altered	20.0% 1/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Renal and urinary disorders Acute kidney injury	20.0% 1/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Renal and urinary disorders Bladder spasm	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Renal and urinary disorders Chronic kidney disease	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	25.0% 1/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.
Renal and urinary disorders Haematuria	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/4 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/5 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	0.00% 0/10 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	12.5% 1/8 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.	14.3% 1/7 • Treatment-emergent adverse events were collected from the first dose of study treatment until the last dose + 30 days; median treatment duration in Part 1 was 11.43 weeks, in Part 2 was 28 weeks, and in the open-label roll-over arm was 75.14 weeks. All-cause mortality was collected from enrollment to end of study visit; median overall duration on study was 259.00 days. Serious adverse events and other adverse events are reported for all participants who received any amount of oprozomib, pomalidomide and/or dexamethasone (safety analysis set) and were collected according to treatment received. All-cause mortality is reported for all participants enrolled in the study and was collected according to assigned treatment group. Participants enrolled in this study from other Amgen studies were included in a single roll-over arm, as pre-specified in the SAP.

Additional Information

Study Director

Amgen Inc.

Phone: 866-572-6436

Email: medinfo@amgen.com

Results disclosure agreements

• Principal investigator is a sponsor employee The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.
• Publication restrictions are in place

Restriction type: OTHER